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CHAPTER 1. INTRODUCTION 
Androgenic hormones, such as dehydroepiandrosterone (DHEA), androstenedione, 
and androstenediol, are sold as nutritional supplements for the purposes of increasing serum 
testosterone concentrations and enhancing the adaptations to resistance training. Use and 
sales of androgenic hormone supplements dramatically increased following the highly 
publicized use of androstenedione by Mark McGwire during the 1998 Major League 
Baseball season when he set a new single season home run record (1,2). 
The purported efficacy of androstenedione as an anabolic agent is based upon a single 
study in which 100 mg androstenedione intake in two women increased serum testosterone 
concentrations ~ 6 fold (3) and a patent application from Germany that claimed remarkable 
increases in serum testosterone following androstenedione intake (4). Despite the popularity 
of androstenedione as a nutritional supplement, there was no evidence that androstenedione 
was an anabolic agent. 
In 1999, King et al. (5) were the first to report that ingesting 100 mg androstenedione 
t.i.d. day does not increase serum testosterone concentrations, muscle mass, or strength in 
young men. Other researchers also reported that ingesting 100 mg androstenedione does not 
increase serum testosterone concentrations (6-8) or increase muscle protein synthesis (8) in 
young men. 
Beginning around age 30, there is a steady decline in serum testosterone 
concentrations as men age (9). Since androstenedione ingestion increases serum testosterone 
concentrations in women (3), who have much lower testosterone concentrations than young 
men, ingesting testosterone precursors may increase serum testosterone concentrations in 
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older men. Therefore, one purpose of this project was to determine the serum testosterone 
response to ingesting 100 mg androstenedione or androstenediol t.i.d. in men 30-60 years 
old. 
While testosterone precursor ingestion has no effect on serum testosterone 
concentrations, ingesting androstenedione or androstenediol does increase serum estrogen 
concentrations (5-8,10). Indole-3-carbinol (I3C) and chrysin are herbal extracts reported to 
prevent the aromatization of androgens into estrogens (11-14). Hence, ingesting I3C and 
chrysin in conjunction with testosterone precursors may prevent the conversion of the 
testosterone precursors into estrogens. 
Androstenedione and androstenediol can also be converted to dihydrotestosterone 
(DHT) (15,16). Saw palmetto and gamma linolenic acid (yla) are herbal extracts that may 
inhibit the enzyme 5a reductase that converts androgens into DHT (17-20). Thus, ingesting 
saw palmetto and yla may prevent the conversion of testosterone precursors into DHT. 
Tribulus terrestris (TT) is an herbal extract claimed to enhance serum luteinizing 
hormone concentrations with a subsequent increase in serum testosterone, although this has 
not been proven. 
Hence, the use of chrysin, I3C, saw palmetto, yla, and TT in conjunction with 
testosterone precursors may prevent the conversion of testosterone precursors into estrogens 
or DHT, resulting in increased serum testosterone concentrations. Although ingesting a 
nutritional supplement that contains androstenedione, DHEA, saw palmetto, TT, I3C, and 
chrysin does not increase serum testosterone concentrations in young men (21 ), the effects of 
a nutritional supplement that combines herbal extracts with testosterone precursors in older 
men is unknown. Another purpose of this project was to determine the hormonal response to 
testosterone precursor nutritional supplements that include herbal extracts in older men. 
Ingested androgens are subjected to a digestive catabolism and hepatic extraction, 
limiting the amount of testosterone precursor that can enter the circulation and be converted 
to testosterone (22,23). The hormonal response to a testosterone precursor administered in a 
manner that bypasses digestion and first pass catabolism is currently unknown. The final 
purpose of this project was to determine the acute hormonal response to a mode of androgen 
delivery that bypasses digestion and first pass catabolism. 
Dissertation Organization 
Following this introduction and a review of literature, four manuscripts addressing the 
effects of androgenic hormone supplementation in men will be presented as separate 
chapters. 
Chapter 3: Brown, G.A., M.D. Vukovich, E.R. Martini, M.L. Kohut, W.D. Franke, 
D A. Jackson, and D.S. King. Endocrine response to chronic 
androstenedione intake in 30-56 year old men. J Clin Endocrinol Metab. 
85:4074-4080, 2000. 
Chapter 4: Brown, G.A., M.D. Vukovich, E.R. Martini, M.L. Kohut, W.D. Franke, 
D A. Jackson, and D.S. King. Effects of androstenedione-herbal 
supplements on serum sex hormone concentrations in 30-59 year old 
men. IntJ Vitam Nutr Res. 71: 293-301, 2001. 
Chapter 5: Brown, G.A., M.D. Vukovich, E.R. Martini, M.L. Kohut, W.D. Franke, 
D A. Jackson, and D.S. King. Endocrine and lipid responses to chronic 
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androstenediol-herbal supplementation in 30 to 58 year old men. J Am 
CollNutr. 20: 520-528, 2001. 
Chapter 6: Brown, G.A., E.R. Martini, B.S. Roberts, M.D. Vukovich, and D.S. 
King. Acute hormonal responses to sublingual androstenediol intake in 
young men. JAppl Physiol. 92: 142-146, 2002. 
The final chapter discusses the conclusions that can be drawn from this body of work, 
and future directions for research. Since chapters 3-6 are previously published works, the 
figures will be referred to numerically as they are in the original publications and not 
sequentially by order of appearance in this dissertation. 
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CHAPTER 2. REVIEW OF LITERATURE 
Introduction 
Steroid biosynthesis is a complex process beginning with cholesterol, either from 
dietary sources or de novo synthesis, and ending with urinary excretion (Figure 1). Steroid 
hormones are formed in the adrenal glands, testes, and ovaries. In addition, 
Cholesterol 
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Figure 1. Pathways of steroid biosynthesis and interconversion. 
there is a great deal of hormonal interconversion that occurs within adipose tissue, muscle 
tissue, and other peripheral tissues (15,16,24,25). This review of literature will explore the 
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formation and interconversion of steroid hormones, the biological effects of these hormones, 
and the current state of knowledge regarding the use of androgens as nutritional supplements. 
Sex Steroids 
Sex steroids are cholesterol-derived hormones that influence the development of 
primary and secondary sex characteristics. Androgenic hormones are C-19 steroids that 
contribute to the development of male reproductive function. In addition to their role in the 
development of sexual characteristics, some androgenic hormones also have muscle building, 
or anabolic, properties (15,26,27). 
Estrogenic hormones are C-18 steroids that have effects not only on feminine breast 
development, but also on bone growth, vascular structure and function, mental development, 
and reproductive function in both genders. Estrogens may counteract or accentuate the 
effects of androgens, depending upon the target tissue (28-31). 
The formation of steroids from cholesterol is a complex process that involves 
multiple enzymatic steps and intermediary hormones. Once formed, androgens are converted 
into estrogens, DHT, or inactive metabolites in the peripheral tissues (Figure 1). Steroids are 
eliminated from the body in the form of inactive, glucuronidated metabolites and active 
urinary metabolites such as DHT and estriol (15). 
Testosterone 
Testosterone ( 17P-hydroxyandrost-4-en-3-one) is the principal androgen, formed 
primarily in the ovaries in females and testes in males. The secretion of testosterone is 
regulated by the hypothalamus through the release of luteinizing hormone (LH). 
Testosterone is formed from cholesterol, which is synthesized de novo or derived from low-
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density lipoproteins. Testosterone is also formed from precursor steroids such as 
androstenedione in peripheral tissues. 
Testosterone has both androgenic and anabolic properties. Normal serum 
testosterone concentrations are -10-20 fold higher in men than those found in women, which 
accounts for the larger muscle mass and strength commonly observed in males (15,32). Only 
testosterone free from sex-hormone-binding globulin (SHBG), representing -2% of the total 
plasma testosterone (free, or bio-available, testosterone), is available for metabolism. Of the 
testosterone not available for metabolism, -60% is bound to SHBG, and the remaining -38% 
is bound to albumin (15,33-35). 
Roughly one half of the daily excretion of testosterone metabolites is in the form of 
urinaiy androstenedione and etiocholanolone. The remaining urinary steroids are in the form 
of polar metabolites (diols, triols, and conjugates) formed from testosterone as a prohormone. 
These urinary metabolites are predominantly inactive (15,22). 
Testosterone can be irreversibly converted to active metabolites such as DHT and 
estrogens (15,24,25,36,37). Dihydrotestosterone has no apparent effect on skeletal muscle 
(38) but has a higher binding affinity for both the androgen receptor and SHBG than does 
testosterone, making DHT a potent mediator of testosterone activity (35,39). 
Dihydrotestosterone, which is a 5a reduced steroid, has been linked to prostatic hypertrophy 
(40-43). In males, the majority of estrogens are formed by aromatization of androgens in the 
central nervous system and peripheral tissue (15,24,37). Estradiol formation involves 
sequential hydroxylation, oxidation, removal of the C-19 carbon, and aromatization of the A 
ring of testosterone. Of the 45 jig of estrogens produced each day by the average young man, 
85-90% is from aromatization with the rest being directly formed in peripheral tissue (15,44). 
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Aging and Testosterone. In men, serum total testosterone concentrations remain constant 
throughout much of adulthood, and do not decline until the 7th or 8th decade of life. 
However, serum free testosterone concentrations peak in the third decade of life, and then 
gradually decrease throughout the remaining years due primarily to an increase in SHBG 
concentrations (9,27,45,46). This age-related decline in serum free testosterone 
concentration is thought to contribute to the reduced muscle mass, loss of libido, and 
increased adiposity in aged men (27,47). 
Testosterone and Muscle Mass. Testosterone stimulates muscle protein synthesis by 
activating a nuclear hormone receptor complex that increases mRNA and DNA synthesis 
(15,48,49). Plasma testosterone concentrations increase transiently due to a bout of 
resistance exercise (50-53). Although resistance exercise does not alter serum testosterone 
concentrations beyond a transient increase (33,54,55), resistance exercise promotes increased 
muscle mass indicating that this brief elevation in serum testosterone has an effect on muscle 
protein synthesis. 
Testosterone Administration. Anabolic steroids are exogenous substances taken either orally 
or intramuscularly to mimic or enhance the effects of testosterone on muscle protein 
synthesis. Early research indicated that anabolic steroids may not increase muscle mass or 
strength (56-58). However, many of these early studies used insufficient doses to cause an 
anabolic effect (56,59-61). Bhasin et al. (62) were the first to demonstrate conclusively that, 
when given in sufficient doses, anabolic steroids result in increased muscle mass and 
strength. Although the use of anabolic steroids is banned in many sports and the use of 
anabolic steroids is associated with negative health consequences (61,63), anabolic steroids 
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have an important therapeutic role in the treatment of hypogonadism (64-66), age-related 
androgen deficiency (67), and muscle wasting diseases (68). 
Mode of Delivery. Oral ingestion of testosterone produces minimal effects on muscle mass 
and serum testosterone concentrations, due to the processes of digestive breakdown and 
hepatic catabolism. Morton and Tait (23) observed that as much as 89% of an ingested 
androgen is destroyed by the digestive process. Of the remaining androgen that reaches the 
blood, -98% is destroyed by hepatic catabolism. Thus, very little of an ingested androgen 
reaches the target tissues. 
Therefore, effective testosterone administration requires administration in a route that 
avoids digestion and hepatic extraction. One such method is sublingual administration, with 
the androgen being absorbed by the oral submucosa. Unfortunately, androgens are 
hydrophobic molecules that are not effectively absorbed across the submucosal membranes. 
However, the combination of testosterone with cyclodextrins, a starch-derived molecule that 
forms a hydrophilic inclusion complex with an androgen, increases in serum testosterone 
concentrations (64,65,69-71). Intramuscular injection of testosterone enanthate is another 
method of delivery that avoids digestion and hepatic catabolism and is frequently used for 
testosterone replacement therapy and as an anabolic agent (48,62,67). Another successful 
mode of androgen administration is ingested synthetic testosterone analogs (such as 
methandienone, stanozolol, and nandrolone) that are not destroyed by digestion and hepatic 
catabolism. However, these substances have more pronounced side effects than do other 
mode of testosterone administration (57,72,73). 
Side Effects with Anabolic Steroid Use. Abnormally high concentrations of serum 
testosterone are associated with abnormal cholesterol metabolism (74,75). The use of 
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anabolic steroids is associated with a decrease in serum high-density lipoprotein cholesterol 
concentrations (HDL-C) (76,77) and specifically HDL-2, due to an increase of hepatic 
triglyceride lipase activity (78). The reduced HDL-C associated with anabolic steroid use is 
reversed once steroid use has been discontinued (68,79). 
Use of exogenous testosterone and anabolic steroids is associated with impaired 
gonadal function due to negative hypothalamic-pituitary-adrenal feedback as evidenced by 
reduced serum LH and follicle stimulating hormone (FSH) concentrations. This impaired 
gonadal function results in lowered production of endogenous testosterone and impaired 
reproductive function (68,79). Although it has generally been thought that gonadal function 
returns after steroid use has been discontinued, it now appears that prolonged use of anabolic 
steroids may result in permanent hypogonadism (80). 
Other negative side effects associated with anabolic steroid use include 
masculinization of women, gynecomastia in men, psychological dependency, aggression, 
baldness, and prostate enlargement (68,79). These side effect are not all directly related to 
testosterone, but are caused by the conversion of testosterone to DHT or estradiol. 
Dehydroepiandrosterone 
Dehydroepiandrosterone (3P-hydroxy-5-androsten-17-one) is formed from 17a 
hydroxypregnenolone via 17, 20 lyase primarily in the adrenal glands. 
Dehydroepiandrosterone and its sulfate ester, DHEA-S, are the most abundant steroids in the 
circulation. Serum concentrations of DHEA peak in the third decade of life and then 
progressively decline with advancing age (15,81). In spite of the large quantities of DHEA 
in the blood, its physiologic role is unclear. 
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Once formed, DHEA is converted to androstenedione via 3 (3 hydroxysteroid 
dehydrogenase (3(3 HSD) (40,82) or androstenediol via 17(3 hydroxysteroid dehydrogenase 
(17(3 HSD) (83). Dehydroepiandrosterone is also converted to estrogens or inactive 
metabolites (15,40). It appears that the primary fate of endogenous DHEA is conversion to 
other hormones (84,85), with DHEA being an estrogen precursor in men and an androgen 
precursor in women (83,86). 
DHEA Intake. The use of DHEA as a nutritional supplement is advertised to enhance 
feelings of health and vitality, provide anti aging benefits, as well as reduce obesity and 
improves athletic performance. However, research on DHEA intake has produced mixed 
results. 
Ingesting DHEA increases serum DHEA and androstenedione concentrations in men 
and women alike (87-92). Ingesting DHEA also increases serum testosterone and DHT 
concentrations in women (89-91,93) but not in men (87-92). Ingesting DHEA also does not 
alter serum estrogen concentrations in men (88-92) except those over age 70 (87). The lack 
of change in serum testosterone or estrogens in spite of increased serum DHEA and 
androstenedione with DHEA ingestion is difficult to explain. 
Labrie et al. (94) found that DHEA administration results in the formation of only 
inactive steroid metabolites in serum. They suggested that the inactive steroid metabolites 
formed with DHEA use indicate intracellular conversion of the DHEA into potent androgens, 
such as testosterone, which are then rapidly converted into inactive metabolites before 
moving into the circulation. This intracrine conversion of ingested DHEA to active steroids 
suggests that DHEA intake should provide anabolic effects. 
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Despite of a lack of change in serum testosterone with DHEA intake, Nestler et al. 
(95) found that when young men ingested 1,600 mg/day DHEA for 4 weeks, body fat mass, 
assessed via skinfold measurement, was reduced by 31 percent. However, these results were 
not duplicated when Welle et al. (92) administered 1,600 mg/day DHEA to men and assessed 
body composition with more precise measurements (total body water and total body 
potassium). In addition, ingesting DHEA did not enhance muscle mass or strength gains 
associated with resistance training (88,96). Therefore, in spite of the potential for DHEA to 
be converted into testosterone, DHEA intake does not alter body composition or muscle 
strength in men, and is thus not likely to be an anabolic substance. 
Side Effects with DHEA Intake. The use of DHEA as a nutritional supplement is associated 
with hirsutism, acne, reduced serum HDL-C, and insulin resistance in women (89,90,93). In 
men, it appears that DHEA intake is free from negative side effects (88-92,95,96) aside from 
elevated estrogens in men over 70 years of age (87). 
Androstenedione 
Androstenedione (Androst-4-ene-3, 17-dione) is formed primarily in the adrenal 
glands, either from DHEA through 3p HSD (82) or from 17a hydroxyprogestrone via 17,20 
lyase (97). Androstenedione has little androgenic or anabolic properties, and appears to be 
primarily a precursor to other hormones (15,98). Androstenedione is reversibly converted to 
testosterone via 17PHSD (97), Horton and Tait (23) observed that testosterone converted to 
androstenedione more readily than androstenedione converted to testosterone. 
It is currently unclear whether androstenedione is converted directly into DHT via 5a 
reductase, or first converted to testosterone and then into DHT. Regardless of the steps in the 
conversion of androstenedione into DHT, Longcope and Fineberg (16) estimated that 14% of 
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circulating DHT arises from the 5a reduction of androstenedione in adipose tissue alone 
indicating that androstenedione is a significant precursor for circulating DHT in men. 
P4S0 Aromatase 
Km= 27 nmol/L 
Vmax = 0.09 pmol/g/h Estrogens 
P450 Aromatase 
Km - 25 nmol/L 
Vmax = 0.072 pmol/g/h 
Dihydrotestosterone 
5a Reductase 
Androstenediol 
3$ HSD 
Km = 290 nmol/L 
y max = 0.0098 pmol/g/h Testosterone 
5a Reductase 
Km = 120-211 nmol/L 
Vmax = 0.025pmol/g/h 
Androstenedione 
17$ HSD 
Km = 1,500 nmol/L 
y~ 0.0084 pmol/g/h 
Figure 2. Enzyme kinetics for selected enzymes of androgen formation. 
Bruch et al. (102) concluded that the limiting factor in the conversion of 
androstenedione to DHT is substrate availability and enzymatic kinetics. Androstenedione is 
also converted into estrone via P450 aromatase (15), and then to estradiol via 17(3 HSD (97). 
Longcope et al. (24) observed that the majority of circulating estrogens in men arise from 
peripheral conversion of androstenedione. The major site for aromatization is adipose tissue; 
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5a reduction is prostatic tissue, and 17p HSD activity in skeletal muscle. Based on studies in 
these tissues, the enzyme kinetics for aromatase in adipose tissue (Km = 25 nmol»L"', Vmax = 
0.072 pmol/g/h) (99) and 5a reduction in prostate (Km = 120-211 nmol*L"', Vmax = 0.025 
pmol/g/h) (36,100) of androstenedione favor the production of estrogens and DHT compared 
to the 17P-HSD conversion of androstenedione to testosterone in skeletal muscle (Km= 1,500 
nmol*L"', Vmax = 0.0084 pmol/g/h) (97,101) (Figure 2). Based on the kinetic data and studies 
with radiolabeled androstenedione, it appears that androstenedione is not converted 
appreciably to testosterone in men, and is unlikely to be an effective testosterone-enhancing 
agent. 
While this data on steroidogenic enzyme activity indicates that androstenedione does 
not alter serum testosterone, but increases DHT and estradiol concentrations, it is important 
to note that this data does not necessarily reflect the activity of enzymes in vivo. Enzyme 
activity in vivo can be altered due to transient or localized changes in pH, temperature, the 
endocrine milieu, or any combination of these. In addition, steroidogenic enzyme activities 
are altered by age, gender, and vary by tissue (36,97,100). Finally, a favorable Vmax may 
mitigate an unfavorable Km. These considerations make it very difficult to predict the 
response to androstenedione administration without in vivo testing. 
Androstenedione Intake. In spite of the above-mentioned data, androstenedione as a 
nutritional supplement has been widely advertised as a testosterone enhancer and anabolic 
agent. Support for this claim is provided from a single study in 1962, in which serum total 
testosterone concentrations were increased approximately 5 fold after two women ingested 
100 mg androstenedione (3). In addition, a German patent application claimed that a single 
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dose of 50 mg androstenedione increased serum testosterone by more than 100% and 100 mg 
increased serum testosterone by more than 300% (4). 
In 1998, when Mark McGwire was in the process of setting a Major League Baseball 
single season home run record, it was discovered that he was using androstenedione. Sales 
of androstenedione increased dramatically after this revelation (1). In spite of the success of 
Mr. McGwire and the popularity of androstenedione as a nutritional supplement, there was 
no scientific evidence evaluating the ergogenic effects of androstenedione intake. 
King et al. (5) were the first to report that ingesting 100 mg androstenedione does not 
acutely increase serum testosterone concentrations in college-aged men or alter serum 
testosterone concentrations or enhance the gains in muscle mass or strength during an 8 week 
resistance training program in college aged men. Others have subsequently reported that 
ingesting androstenedione in doses of 50 - 100 mg does not increase serum testosterone 
concentrations (6-8,21), enhance the adaptations to resistance training (10,21,96), or promote 
muscle protein synthesis (8). 
In contrast to the reports that 50-100 mg androstenedione intake does not alter serum 
testosterone concentrations in men (6-8,21), two reports have indicated that androstenedione 
intake increases serum testosterone when taken in larger doses (6,103). Earnest et al. (103) 
reported that serum testosterone concentrations were higher during 90 min following the 
ingestion of 200-mg androstenedione compared with placebo. However, neither free nor 
total testosterone concentrations were significantly higher at any time point following 
ingestion of androstenedione. It addition, it appears that the area under the curve, as 
calculated by these authors, included the area attributable to baseline which was higher 
during the androstenedione trial. Leder et al. (6) reported that serum testosterone 
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concentrations in young men were not altered by ingesting 100 mg androstenedione but were 
increased by 34% during 8 h following a single 300-mg dose. Taken together, the data 
indicate that serum testosterone concentrations in young men are not altered by 
androstenedione intake unless the dose is at least 300-mg. There has not been an effort to 
evaluate any possible age related response to androstenedione intake. 
Side Effects with Androstenedione Intake. Prolonged androstenedione intake is associated 
with reduced serum HDL-C (5,10,21) and increased serum estrogen concentrations 
(5,6,10,21). It appears that androstenedione intake in doses up to 300 mg/day does not 
change serum LH or FSH concentrations, suggesting no negative hypothalamic-pituitary-
adrenal feedback (5,21). Interestingly, androstenedione intake in rats causes enlargement of 
the aggression center of the brain (104), suggesting that androstenedione intake could cause 
"Roid Rage" similar to anabolic steroids. However, this effect has not been scientifically 
investigated in humans. The effect of androstenedione intake on serum DHT or prostate 
function is currently unknown. 
Androstenediol 
Androstenediol (4-androstene-3|3, 17|3-diol) is a weak adrenal androgen formed from 
DHEA via 170 HSD (82,83). The physiologic role of androstenediol appears to be primarily 
as a precursor to other hormones. Once formed, androstenediol can be converted to 
testosterone via 30 HSD (83,105) or aromatized to estrogens (105) in the peripheral tissues. 
The enzyme kinetics for aromatase (Km=27 nmoI«L"\ V^x = 0.09 pmol/g/h) (99) and 30 
HSD (Km=290 nmol*L~', Vmax = 0.0098 pmol/g/h) (101) favor the conversion of 
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androstenediol to estrogens over testosterone. Currently, no data on the enzyme kinetics for 
the 5a reduction of androstenediol to DHT are available. 
Blaquier et al. (106) reported that 15% of androstenediol is converted to testosterone. 
However, this research was conducted in tritiated blood and thus did not measure the rate of 
conversion in peripheral tissue, nor did it measure the conversion of androstenediol to other 
steroids. 
Androstenediol Intake. Based upon the results from Blaquier et al. (106) androstenediol has 
been advertised as a better alternative for testosterone enhancement, and subsequent gains in 
muscle mass and strength, than is androstenedione. Although the enzyme kinetics for the 
conversion of androstenediol to testosterone (Km=290 nmol*L"') are more favorable than 
those for the conversion of androstenedione to testosterone (Km= 1,500 nmol*L"') (101), the 
Km is in excess of 10 fold greater than the normal physiologic levels. In addition, the 15% 
rate of conversion of androstenediol to testosterone reported by Blaquier et al. (106) is nearly 
the same as the 14% conversion rate for androstenedione to testosterone reported by Horton 
and Tait (23). 
Currently, there have only been 2 studies regarding the use of androstenediol as a 
nutritional supplement. Earnest et al. (103) reported that ingesting a single dose of 200 mg 
androstenediol does not acutely increase serum testosterone concentrations in young men. 
Breeder et al. (10) reported that ingesting 100 mg androstenediol b.i.d. does not increase 
serum testosterone concentrations or enhance the adaptations to resistance training in 35-65 
year old men. 
Side Effects with Androstenediol Intake. Prolonged androstenediol intake causes reduced 
serum HDL-C and increased serum estrogens (10). There have been no investigations on the 
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psychological effects of androstenediol intake. The effect of androstenediol intake on serum 
DHT or prostate function is currently unknown. 
Dihydrotestosterone 
Dihydrotestosterone is a major end product of steroid metabolism, being irreversibly 
formed from DHEA, androstenedione, androstenediol, and testosterone via 5a reductase 
(36,40,107). Once formed, DHT binds to the androgen receptor and produces physiologic 
effects or is excreted in the urine (15). 
Dihydrotestosterone binds to the androgen receptor and SHBG more potently than 
does any other androgen (35,39,108). In addition, DHT is the most potent androgen 
responsible for the majority of the reproductive tissue development observed during puberty 
(15,107). Due to the potent androgenicity of DHT, the effect of DHT on the prostate is of 
tremendous interest. Men with benign prostate hypertrophy (BPH) (41,42), but not prostatic 
cancer (39), exhibit elevated serum concentrations of DHT. 
Dihydrotestosterone Intake. Due to the risk of BPH with elevated DHT concentrations, DHT 
is not readily available as a nutritional supplement. However, since DHT cannot be 
aromatized, it has been suggested that DHT administration could be a viable treatment for 
age related sexual dysfunction in men as long as serum estrogen concentrations are not 
increased (109). Antonio et al. (38) observed that DHT administration in rats produced 
hypertrophy of muscles involved in reproductive function, but not other skeletal muscles, 
suggesting that DHT does not produce an anabolic effect in humans. 
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Estrogens 
Estrogens are formed in the ovaries or in peripheral tissue through the aromatization 
of androgens (31,110). The importance of extragonadal production of estrogens to human 
health has just recently begun to be understood (29). 
There are three primary estrogens in the circulation. Estrone (El) is formed from the 
aromatization of androstenedione, and has weak estrogenic effects. Kley et al. ( 111 ) 
observed that there is an increase in aromatization of androstenedione in men who are 20% 
over ideal body weight. The primary function of El is a precursor to estradiol (E2) (15). 
Estradiol, the most potent circulating estrogen, is formed from the aromatization of 
testosterone, or from the conversion of estrone through the action of 17p HSD (15,97). 
Estriol (E3) is a weak estrogen that can be formed from E2. Serum concentrations of E3 are 
normally very low in men and women. The primary source of circulating estriol is the 
placenta (15). 
Although estrogens have protective effects for heart disease by enhancing venous 
compliance and HDL-C synthesis (29,112), elevated serum estrogens in men have been 
linked to myocardial infarction (113). Elevated serum estrogen concentrations in men have 
also been linked to gynecomastia (61,114,115). In youth, elevated serum estrogen 
concentrations can cause premature epiphyseal closure (28). In addition, prostate 
hypertrophy can occur when serum estrogen and DHT concentrations are elevated (40,43). 
Summary 
Testosterone is the principal anabolic androgen, while DHEA, androstenedione, and 
androstenediol primarily function as reversible precursors to other androgens or estrogens. 
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Dihydrotestosterone is an irreversible 5a reduced end product of androgen metabolism and is 
the most potent androgen. 
Testosterone administration can enhance muscular strength and size, but is banned in 
most sports, has numerous undesirable, and dangerous, side effects. Androstenedione, 
androstenediol, and DHEA are marketed as testosterone enhancing/muscle building 
nutritional supplements. In spite of the advertised claims, intake of testosterone precursors 
does not enhance muscle strength or serum testosterone concentrations, but does increase 
serum estrogen and DHT. The enzyme kinetics associated with androstenedione and 
androstenediol favor the production of end product metabolites, such as DHT and estrogens, 
rather than testosterone (Figure 2). 
Herbal Extracts 
As a result of the 1994 Dietary Supplement Health education Act (DHSEA), a large 
number of herbal products have been marketed as nutritional supplements. Many of these 
herbal extracts are advertised to enhance athletic performance. Some of these herbal 
supplements are purported to increase serum testosterone concentrations. 
Chrysin and I3C may prevent the aromatization of androgens. Saw palmetto and yla 
may prevent the 5a reduction of androgens. Tribulus terrestris is purported to increase serum 
LH with a resulting increase in serum testosterone concentrations. By using these herbal 
extracts in combination with testosterone precursors, the hormonal response to androgen 
intake may be altered. 
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Chrysin 
Chrysin is a flavonoid from passion flower (Passiflore caerulea). Flavonoids are 
ubiquitous plant compounds with numerous biological properties. Flavonoids have been 
found to have estrogenic, antiestrogenic, and aromatase inhibitory capabilities (116). 
Flavonoids may prevent the aromatization of testosterone by competing with the 
steroids for enzyme binding sites. Chrysin has been shown, in vitro, to inhibit P-450 
aromatase, the enzyme responsible for aromatization (116). It has been advertised that by 
inhibiting the aromatization of androgens, testosterone levels will remain high. However, we 
have recently observed that intake of 675 mg/day chrysin along with 300 mg/day 
androstenedione does not prevent the increase in serum estrogens associated with 
androstenedione intake or increase serum testosterone concentrations (21). Since there are 
age related changes in gonadal function and steroidogenesis, it is possible that older men may 
respond to chrysin intake differently than do young men. 
Indole-3-Carbinol 
Indole-3-carbionol is a plant extract from cruciferous vegetables such as cabbage. 
Indole-3-carbinol inhibits aromatization and enhances urinary estrogen clearance. Ingesting 
a diet high in I3C (400-500 mg/day) has been observed to reduce serum estrogens in men and 
women (12-14,117). 
It has been advertised that ingesting I3C in conjunction with testosterone precursors 
will prevent the increased serum estrogens associated with testosterone precursor intake. 
However, we have recently observed that ingesting 300 mg/day I3C along with 300 mg/day 
androstenedione does not prevent increased serum estrogens or cause elevated testosterone 
concentrations in young men (21). Since there are age related changes in gonadal function 
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and steroidogenesis, it is possible that older men may respond to I3C intake differently than 
do young men. 
Saw Palmetto 
Saw palmetto (Serenoa repens B) is a type of palm tree found on the southern 
Atlantic coast of the United States. An extract from the berries of the saw palmetto plant, 
also called permixon, is used to treat BPH ( 17). 
Saw palmetto extract prevents DHT from binding to the androgen receptor (17,118). 
Saw palmetto extract has also been observed to prevent estrogen and DHT formation through 
competitive binding with aromatase and 5a reductase (18,19,119). However, this research 
has been conducted in vitro, which may limit the utility of these findings. 
Ingesting 160 mg saw palmetto extract per day does not alter serum testosterone, LH, 
or FSH concentrations (19). We have recently observed that ingesting 540 mg/day of saw 
palmetto extract in conjunction with 300 mg/day of androstenedione does not alter the 
hormonal response to androstenedione intake in young men (21). We were unable to 
measure serum DHT or prostate specific antigen (PSA) concentrations, and so were unable to 
evaluate the effect of saw palmetto and androstenedione intake on the 5a reduction of 
ingested androgens or prostate health. 
Tribulus terrestris (Genus species) 
Tribulus terrestris is a plant commonly known as puncture vine. Ingesting TT extract 
is advertised to enhance serum testosterone concentrations by increasing serum LH 
concentrations. Although the effects of ingesting TT alone on serum testosterone and LH 
concentrations has not been investigated, we have recently observed that ingesting 750 
mg/day of TT along with 300 mg/day androstenedione does not alter serum testosterone or 
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LH concentrations (21 ). However, the effect of ingesting TT and testosterone precursors has 
not been investigated in older men. 
Gamma Linolenic Acid 
Gamma linolenic acid is a C-18 unbranched fatty acid with three double bonds at 
positions 6,9, and 12, all in the cis configuration. Liang and Liao (20) reported that, in rat 
liver microsomes, concentrations of ~10 pM yLA both decreased the Vmax and increased the 
Km of 5a reductase without altering the activity of 17(3 HSD. It is difficult to classify this 
type of inhibition, since competitive inhibitors increase the Km while non-competitive 
inhibitors decrease the Vmax, suggesting that yLA is a universal inhibitor of 5a reductase. In 
addition, this research was conducted in vitro, which limits the applicability of this research 
to nutritional supplements in vivo. 
Summary 
Numerous herbal extract are marketed to promote testosterone formation. Although 
chrysin, I3C, saw palmetto, yLA, and TT are advertised to alter steroid formation in favor of 
increased serum testosterone concentrations, most of these products have not been 
investigated in vivo. In addition, while these products have been shown effective in vitro, 
and not in conjunction with exogenous androgen administration. Therefore, the utility of 
chrysin, I3C, saw palmetto, yLA, and TT to prevent changes in serum estrogens and DHT 
associated with testosterone precursor intake needs to be evaluated. 
We have recently observed that when chrysin, I3C, saw palmetto, and TT are taken in 
conjunction with androstenedione and DHEA in young men, there is no change in the 
hormonal response compared to that when taking only androstenedione. However, since 
there is an age related change in serum steroid concentrations, ingesting chrysin, I3C, saw 
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palmetto, yLA, and TT may alter the hormonal response to testosterone precursor intake in 
older men. 
Conclusion 
In spite of the popularity of testosterone precursor nutritional supplements, these 
products do not cause physiologically significant changes in serum testosterone 
concentrations. Much of the research involving the use of testosterone precursors has used 
young men who already have high endogenous testosterone concentrations. Since serum 
testosterone concentrations decline with age, and basal endogenous testosterone 
concentrations may alter the hormonal response to testosterone precursor intake, one purpose 
of this project is to determine if age influences the hormonal response to testosterone 
precursor intake. 
There are currently numerous herbal extracts that are claimed to alter enzyme 
function and prevent the aromatization or 5a reduction of androgens. Most of these products 
have not been tested in vivo or in the presence of exogenous androgens. Another purpose of 
this project is to determine if combining herbal extracts with testosterone precursors alters 
the hormonal response to nutritional supplements. 
Ingested androgens are subjected to a large amount of digestive and hepatic 
catabolism, limiting the amount of testosterone precursor that enters the extra hepatic 
circulation, which may prevent the formation of testosterone from the ingested androgen. A 
final purpose of this project is to determine if sublingual cyclodextrin androstenediol 
increases serum testosterone concentrations in men. 
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Abstract 
In young men chronic ingestion of 100 mg androstenedione three times per day does not 
increase serum total testosterone, but does increase serum estrogen and androstenedione 
concentrations. We investigated the effects of androstenedione ingestion in healthy 30-56 
year old men. In a double blind, randomly assigned manner, subjects consumed 100 mg 
androstenedione three times daily (ASD; n=28) or placebo (PL; n=27) for 28 days. Serum 
androstenedione, dihydrotestosterone, free and total testosterone, estradiol, prostate specific 
antigen, and lipid concentrations were measured at week 0, and each week throughout the 
supplementation period. Serum total testosterone and prostate specific antigen 
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concentrations did not change with supplementation. Elevated serum concentrations of 
androstenedione (300%), free testosterone (45%), dihydrotestosterone (83%), and estradiol 
(68%) were observed during weeks 1-4 in ASD (P<0.05). There was no relationship between 
age and changes in serum androstenedione (1^=0.024), free testosterone (r^-0.00) or estradiol 
(1^=0.029) concentrations with ASD, while the serum dihydrotestosterone response to ASD 
ingestion was related to age (r2=0.244; P<0.05). Serum concentrations of HDL-C were 
decreased by 10% during the supplementation period (P<0.05). These results suggest that 
the ingestion of 100 mg androstenedione three times per day does not increase serum total 
testosterone or PSA concentrations, but does elicit increases in androstenedione, free 
testosterone, estradiol, dihydrotestosterone, and decreases serum HDL-C concentrations. 
Introduction 
Recently, the ingestion of pro-hormone nutritional supplements has been purported to 
increase serum testosterone concentrations. In two women, ingestion of a single 100-mg 
dose of androst-4-ene-3, 17-dione (androstenedione) elevated serum testosterone 
concentrations approximately 600% within 60 min ( 1 ). However, in young men ingestion of 
100- or 200 mg of androstenedione does not change serum testosterone concentrations (2-6) 
while ingesting a single 300-mg dose of androstenedione promotes a smaller (34%) increase 
in serum total testosterone concentrations that persists for 4-6 h (5). Women have lower 
basal serum testosterone concentrations than men and serum testosterone concentrations 
decline with age in men (7-9). Therefore, it is possible that basal serum testosterone 
concentrations, as well as age, may influence the effects of androstenedione ingestion on 
serum testosterone concentrations. 
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Recently, Wallace et al. (10) examined the effects of ingesting 100 mg/day 
androstenedione for 12 wk on serum testosterone, DHEA, androstenedione, prostate specific 
antigen (PSA) and insulin-like growth factor-1 in 40-60 year old men. The hormonal and 
lipid response to a larger dose of androstenedione in older men is unknown. Therefore, we 
evaluated the effects of 100 mg androstenedione three times per day four 28 days on serum 
free testosterone, total testosterone, estradiol, dihydrotestosterone, prostate specific antigen, 
and serum lipid concentrations in 30 - 56 year old men. Wallace et al. (10) found no 
differences in measurements of well-being and libido between placebo and 100- mg day"' 
androstenedione ingestion in older men. Therefore, we also evaluated the effect of chronic 
androstenedione ingestion on perception of mood states in 30-56 year old men. 
Methods 
Subjects 
Fifty-six men, aged 30 through 56, were recruited from the university and local 
community to participate in this project. All subjects signed an informed consent and 
completed a written medical history to eliminate any subjects with any known chronic 
disease. Prior to participating in this study subjects were questioned to ensure they were not 
currently or previously using nutritional supplements. The Iowa State University human 
subjects review board approved this study. Subjects were stratified into age groups 
representing the fourth (30 year olds, n=20), fifth (40 year olds, n=20), and sixth (50 year 
olds, n=16) decades. 
Supplementation 
Subjects were randomly assigned in a double blind, counter balanced fashion to 
treatment groups consuming capsules containing either placebo (PL) or 300 mg day-' 
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androstenedione in doses of 100 mg taken three times daily (ASD; Experimental and Applied 
Sciences, Golden, CO). An independent laboratory (Integrated Biomolecule, Tuscon, AZ) 
verified purity (-99%) and content of the androstenedione capsules via high performance 
liquid chromatography (HPL-C). Subjects were instructed to consume the supplement 
capsules daily before 9:00 am, at 3:00 pm, and before bedtime in equal doses throughout the 
4 weeks of supplementation. Compliance was monitored through written records of 
supplementation and the return of unused supplements at the completion of the study. 
Diet and Activity 
Subjects were instructed to maintain their normal diet and activity patterns throughout 
the 4-week study period. Subjects were given verbal and written instructions regarding the 
reporting of dietary intake and instructed to maintain a diet, medication, and exercise record 
for the 2 days prior to each blood sampling. The diet and exercise records were collected 
prior to weekly blood sampling and analyzed using commercial software (Nutritionist 4, N-
Squared Computing, San Bruno CA). 
Blood Sample Collection and Analysis 
Fasting blood samples were collected between 6:30 and 8:00 a.m. once per week on 
the same day each week. Subjects reclined while blood samples were obtained without stasis 
from an antecubital vein. Blood samples were immediately placed in an ice bath until 
centrifugation and serum separation. Blood samples were analyzed for lipid, glucose, 
enzyme, and chemical composition by a commercial laboratory (Quest Diagnostics, Wood 
Dale, IL). Serum concentrations of estradiol, total testosterone, free testosterone, and 
androstenedione were measured with commercial radioimmunoassay kits (Diagnostic 
Products Corp, Los Angeles, CA, and Diagnostic Systems Laboratory, Webster, TX). 
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Commercially available enzyme-linked immunosorbent assays (ELISA) were used to 
measure serum concentrations of prostate specific antigen (PSA; Bio-Clin, Inc, St. Louis, 
MO) and dihydrotestosterone (DHT; Immuno-Biological Laboratories, Hamburg, Germany). 
All samples for each subject were analyzed in duplicate within the same assay and the intra-
assay coefficients of variation for total testosterone, free testosterone, estradiol, 
androstenedione, DHT and PSA were 6.1%, 7.2%, 6.6%, 5.8%, 3.2% and 6.6%, respectively. 
According to the suppliers of the RIA and ELISA kits, there is no detectable cross reactivity 
of the assays for androstenedione, DHT, estradiol or testosterone. 
Profile of Mood States 
Subjects completed and returned questionnaires each week assessing perceptions of 
health and well-being (11). Questionnaires consisted of yes or no questions assessing 
changes in libido, symptoms of illness, or mood change for the 3 days prior to blood 
sampling. 
Calculations and Statistics 
Data were analyzed using commercial software (SPSS Inc, Chicago, IL). Statistical 
analyses of age group effects were performed using a 3 factor (week by supplement by age 
group) repeated measures analysis of variance (ANOVA). Specific mean differences (P < 
0.05) were identified using Student Newman-Keuls post hoc comparisons. Relationships 
between the effects of supplementation and measured variables were analyzed using simple 
linear regression. The percent change in serum hormones and blood lipids was calculated as 
the mean percent change in serum concentrations during weeks 1-4. Data are presented as 
means + SE. 
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Results 
Subjects 
Subjects came from diverse occupations and physical activity levels. Regular 
participation in aerobic exercise such as walking, jogging and racquetball was reported in 10 
subjects in PL and 12 subjects in ASD while 6 subjects in PL and 5 in ASD reported regular 
participation in resistance training. Subjects reported no changes in their day-to-day physical 
activity pattern throughout the study duration including the day prior to blood sampling. 
Height, body mass, and body mass index (BMI) were not different between treatment or age 
groups (Table 1). Body mass and BMI were not altered by supplementation. One 50-year-
old subject in the placebo group was diagnosed with non-insulin dependent diabetes mellitus 
during the study, informed of his condition, and his data have been excluded from all 
analyses. 
Dietary Analysis 
There were no significant age or treatment group differences in dietary energy, 
protein, carbohydrate, total fat, saturated fat, or polyunsaturated fat intake. 
Hormonal Response to Supplementation 
Basal serum androstenedione levels were higher in the 30 year olds (P < 0.05) than in 
the 40 or 50 year olds (Figure 1). Ingestion of androstenedione resulted in significant and 
similar mean increases of 268%, 300% and 357% in serum androstenedione concentrations 
throughout the 4 weeks of supplementation for 30,40, and 50 year olds, respectively (P < 
0.05). Mean changes in serum androstenedione concentrations in ASD during weeks 1-4 
were not correlated to age (r2=0.024) or BMI (r2=0.00). 
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Serum total testosterone concentrations were not different among age or treatment 
groups before or during the 4 weeks of supplementation (Figure 2). There was also no age 
related effect of supplementation on serum total testosterone concentrations (r=0.0l8). 
Basal serum free testosterone concentrations were higher in the 30 year olds than in 
the 50 year olds (P<0.05; Figure 3). Ingestion of androstenedione resulted in elevated serum 
concentrations of free testosterone during weeks 1-4 (P<0.05) by 37%, 51%, and 46% for 
the 30,40 and 50 year olds, respectively. The change in serum free testosterone 
concentrations was related to basal free testosterone concentrations (1^=0.284) but not to age 
(1^=0.00) or BMI (r2=0.0379). 
Baseline serum DHT levels were higher in the 30 year olds than in the 40 or 50 year 
olds (Figure 4). Serum DHT was unchanged throughout the 4-week supplementation period 
in PL, while ingestion of androstenedione increased (P<0.05) serum DHT concentrations in 
the 30,40, and 50 year olds by 56%, 81% and 113%, respectively, throughout the 4-week 
supplementation period. There was a significant (P<0.05) relationship between age and the 
mean increase in serum DHT during the four weeks of androstenedione supplementation 
(r2=0.244). Body mass index did not correlate with changes in serum DHT (r2=0.023). 
Basal serum estradiol concentrations were not effected by age. Serum estradiol 
concentrations were significantly and similarly increased throughout weeks 1-4 by 80%, 
55%, and 71% in ASD for 30,40, and 50 year olds, respectively (Figure 5). There was no 
relationship between age and the mean increase in serum estradiol throughout weeks 1-4 in 
ASD (r2=0.029). The mean increase in serum estradiol concentrations throughout weeks 1-4 
was also unrelated to the BMI (r2=0.133). 
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Serum PSA concentrations (Figure 6) were initially higher (P<0.05) for the 50 year 
olds taking ASD (4.4 + 0.6 ng ml"') than any other age or supplement group (2.5 + 0.4 ng ml" 
' for all others combined). However, serum PSA concentrations were not altered during the 
four weeks of supplementation. 
Serum Lipid Response 
Serum HDL-C levels were reduced by 10% (P<0.05) at week 1 in ASD and remained 
depressed throughout the remainder of the 4 weeks of supplementation, with no observed age 
related effect (r2=0.037; Table 2). There was a significant inverse correlation between the 
mean changes throughout week 1-4 in serum androstenedione and HDL-C concentrations 
(r2=0.284). Concentrations of serum low-density lipoprotein cholesterol (LDL-C), total 
cholesterol (Total-C), and the total cholesterol/HDL cholesterol ratio were not changed in 
either ASD or PL. 
Blood Chemistry Response 
Serum concentrations of gamma-glutamyltransferase, aspartate aminotransferase and 
alanine aminotransferase were unchanged throughout the 4-week supplementation period and 
were not affected by age. There were also no age or supplement related change in 
concentrations of serum protein, albumin, globulin or other indices of blood chemistry. 
Profile of Mood States 
Decreased libido was reported on one occasion by two subjects in PL and one 
occasion by one subject in ASD during the 4-week supplementation period while increased 
libido was reported 6 times by 4 subjects in PL and 8 times by 4 subjects in ASD suggesting 
that libido is not altered by androstenedione ingestion. There were no differences between 
PL and ASD in the frequency of reported changes in energy level, memory, stress, appetite, 
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chest pain, headaches, or overall sense of health. The most commonly reported side effect of 
supplementation was heartburn, with an increased frequency of heartburn reported on 13 
occasions by 10 subjects in ASD and five occasions by five subjects in PL. 
Discussion 
The age at which serum testosterone concentrations in men are significantly reduced 
is unclear. Some reports indicate significant decreases in serum total testosterone beginning 
in the fifth (9) or sixth (8) decades of life, while others report relatively stable serum total 
testosterone concentrations through the seventh decade of life (7). There is also 
disagreement regarding the age at which serum free testosterone begins to decline in men (7-
9). However, the current results are in agreement with previous reports that observed very 
small declines in serum total testosterone concentrations with age, while serum free 
testosterone concentrations decline much earlier in life. The age related decline in serum free 
testosterone concentrations while serum total testosterone concentrations remain stable is 
associated with an age-associated increase in sex hormone binding globulin (SHBG) 
concentrations (7-9). 
Two recent studies concluded that serum total testosterone concentrations in men 
increase after ingestion of androstenedione (5; 12). Earnest et al. (12) reported that the 
incremental area under the curve for serum testosterone concentrations during 90 min 
following the ingestion of 200-mg androstenedione was higher compared with placebo. 
However, neither free nor total testosterone concentrations were significantly higher at any 
time point following ingestion of androstenedione. In addition, the values reported for the 
area under the curve apparently included the area attributable to baseline serum testosterone 
concentrations, which were slightly higher in the group of subjects ingesting 
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androstenedione. In agreement with the present results as well as our previous findings (3;4) 
Leder et al. (5) observed that ingestion of 100-mg androstenedione did not increase serum 
total testosterone concentrations. In contrast, these authors observed that serum testosterone 
concentrations during 8 h following a single 300-mg androstenedione dose increased by 
34%. Since blood samples in the current study were collected -10 h after the previous 100 
mg dose of androstenedione it was not possible to assess peak hormonal changes after 
androstenedione ingestion. Our previous research indicates that after ingesting 100 mg 
androstenedione, peak increases in serum androstenedione concentrations occur ~ 120-300 
min after ingestion, while changes in serum estradiol concentrations are not evident during 
the 6 h after ingestion, and serum total testosterone concentrations are not altered (3;4). 
Although transient increases in serum total testosterone after ingestion of 100 mg of 
androstenedione cannot be ruled out, the present results support our previous findings (3;4) 
and those of others (2;5; 10) that total testosterone concentrations are not chronically 
increased by ingestion of androstenedione in doses of up to 300 mg per day, when taken in 
100 mg doses. The current study extends these findings by demonstrating that ingestion of 
100 mg of androstenedione three times daily does not alter serum total testosterone 
concentrations in middle-aged men. 
A novel finding was that while serum total testosterone was unaffected, serum free 
testosterone increased by 37-51% in these 30-56 year old men. These results are in contrast 
to our previous finding that 100 mg of androstenedione three times daily does not chronically 
increase serum free testosterone concentrations in 23 year old men (3;4). Consistent with the 
previously observed age related declines in serum free testosterone concentrations (7-9), the 
serum free testosterone concentrations in the current subjects were lower than in the younger 
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subjects in our previous research (3;4). In addition the mean increase in serum free 
testosterone concentrations during weeks 1-4 was significantly related to basal serum free 
testosterone concentrations in the current study. These findings suggest that oral 
androstenedione ingestion may promote increases in serum free testosterone concentrations 
in men with low serum free testosterone concentrations. 
The finding of unchanged serum total testosterone, albumin, and protein 
concentrations, together with the significant increase in free testosterone concentrations 
suggests that ingestion of 100 mg androstenedione three times daily changes the 
concentration of SHBG bound testosterone. Although androstenedione is a weaker androgen 
than testosterone (13), exogenous testosterone administration decreases serum SHBG 
concentrations (14). In addition, since SHBG may have a greater binding affinity for DHT 
than for testosterone (15), it is also possible that the increase in serum free testosterone 
concentrations we observed was a result of a decoupling of SHBG from testosterone to bind 
with DHT or other steroids. 
The metabolic significance of the transient increase in serum total testosterone 
concentrations found by Leder et al. (5) and the chronic elevation of free testosterone in the 
present study is uncertain. Increased rates of muscle protein synthesis (16) and increased 
muscular strength (14; 16) have been observed after testosterone administration resulting in 
very large increases in serum testosterone concentrations (-100-600%). It is unknown 
whether more prolonged, small elevations in serum testosterone concentrations of the 
magnitude observed in the current study and by Leder et al. (5) would produce measurable 
effects on muscle size and strength. 
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The significant increase in the serum DHT concentrations observed in the current 
study suggests that a significant amount of the elevated serum androstenedione and free 
testosterone underwent conversion to DHT. The conversion of androstenedione to 
dihydrotestosterone can occur in prostate, skin, or adipose tissue, which all contain 
appreciable concentrations of 5a-reductase (13; 17; 18). Longcope and Fineberg (17) 
estimated that 14% of total serum androstenedione is converted to dihydrotestosterone in 
adipose tissue alone. Serum androstenedione concentrations increased by ~ 19 nmol-L"1, and 
serum DHT concentrations increased by -1,500 pmol-L"1 in the present study, corresponding 
to an 8% conversion of androstenedione to DHT. Although the increases in serum DHT 
concentrations were weakly related to age (R2=0.24) consistent with age related increases in 
5a-reductase concentrations (19), the mean DHT concentrations were not different during 
weeks 1-4 in the three age groups. These findings suggest that androstenedione ingestion 
will increase serum DHT concentrations in men of all ages. 
Although DHT is the most potent naturally occurring androgen, the metabolic effects 
of DHT appear to occur primarily in reproductive organs, since skeletal muscle tissue does 
not contain appreciable quantities 5a-reductase (13; 17). Recently, it has been observed that 
the administration of DHT to castrated rats restored the levator ani and bulbocavemosus 
muscles to pre-castration size but had no effect on the size of plantaris muscle (20), 
supporting the notion that the anabolic effect of DHT is limited to tissues involved with 
reproduction. Although we did not measure serum DHT in our previous study in which 
androstenedione intake did not alter muscle size or strength in 19-29 year old men (4), it is 
likely that serum DHT concentrations during supplementation were similar to those observed 
in the present study. Taken together, these findings suggest that the increases in circulating 
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DHT observed in the current study are unlikely to have any anabolic effects on skeletal 
muscle of older men. 
In agreement with previous observations in young men (2-6), ingestion of 
androstenedione caused a significant increase in serum estradiol concentrations in the 
middle-aged-men in the current study providing evidence that a portion of ingested 
androstenedione is aromatized (21 ;22). Aromatization can occur in a number of tissues, 
including adipose tissue (21 ;23;24). While adipose tissue contains aromatase (23) and the 
degree of obesity has been related to enhanced aromatization of androstenedione (25), we 
found no relationship between the change in serum estradiol concentrations and body mass or 
BMI. While our subjects were slightly overweight (110% of ideal body weight), the 
aromatization of androstenedione may not be affected by adiposity until 120% of ideal body 
weight is reached (30). In addition, the enzyme kinetics for the aromatization of 
androstenedione (Km=25 nmol-L"') (23) favor the production of estrogens compared to the 
17p-HSD conversion of androstenedione to testosterone (Km= 1,500 nmol-L"') (26). 
The reduction in serum HDL-C associated with ingestion of 100 mg androstenedione 
three times per day is in agreement with our previous research in young men (3;4). A 
decrease of 0.13 mmol-L"' in serum HDL-C concentrations corresponds to a 10-15% increase 
in the risk of atherosclerotic lesion development (27) and heart disease (28). While ingestion 
of 50 mg androstenedione twice daily for 12 weeks does not alter serum HDL-C in middle 
aged men (10), ingestion of 100 mg androstenedione three times daily reduces serum HDL-C 
concentrations by 15% (present study;3;4), suggesting that the dosage of androstenedione 
may affect the serum lipid response to androstenedione ingestion. 
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While the initial serum PSA concentrations in the 50 year olds consuming ASD were 
above average and may reflect altered prostate function, serum PSA concentrations were not 
changed by supplementation in any age group. The use of PSA measurements to evaluate 
prostate function, however, should be viewed cautiously, For example, it has been reported 
that 30% of patients with prostatic tumors present with normal PSA concentrations, while 
elevated PSA concentrations are found in ~2% of healthy men (29). In addition, since 
elevated serum DHT and estradiol concentrations may cause benign prostate hypertrophy 
(30), and the blockade of adrenal androgens is advised for the remediation of benign prostate 
hypertrophy (18) it is possible that more prolonged androstenedione supplementation may 
result in detectable changes in prostate function. 
Ingesting 50 mg androstenedione twice daily for 12 weeks did not change perceived 
health or mood in middle aged men (10). In the present study there was no difference in the 
perceptions of mood, health, or libido between subjects ingesting placebo or 
androstenedione. Taken together, these results suggest that short-term ingestion of 
androstenedione at the doses of 50 mg twice daily, or 100 mg three times daily, are 
associated with no psychological or emotional benefits. 
The effects of the 55-80% elevation in estradiol concentrations in the current study 
are not clear. Although estrogens may produce favorable changes in lipid profiles and 
cardiovascular reactivity (31), a 21% higher serum estradiol concentration has been observed 
in male subjects experiencing myocardial infarction compared to those with no heart disease 
(32). Increased serum estradiol levels in men have been associated with the development of 
gynecomastia (24). While a cause and effect relationship has not been established, increased 
serum androstenedione concentrations have also been observed in patients with pancreatic 
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carcinoma (33). Thus, the changes in the hormonal milieu associated with androstenedione 
ingestion may increase the risk for additional adverse health consequences. 
While there has been speculation that consumers of androstenedione use doses much 
higher than have been studied (34), the dosage of androstenedione used by consumers and 
the effects of larger doses of androstenedione are unknown. Moreover, it is likely that any 
possible benefit of raising serum testosterone concentrations by ingesting higher doses of 
androstenedione would be associated with larger increases in serum estradiol, DHT, and a 
larger decrease in serum HDL-C concentrations. 
In summary, ingestion of 100 mg androstenedione three times per day did not alter 
serum total testosterone concentrations in 30-56 year old men. Ingestion of androstenedione 
produced elevated serum free testosterone, androstenedione, estradiol, and 
dihydrotestosterone concentrations, and reduced serum HDL-C concentrations. There was 
also no change in perceived mood, health, or libido associated with androstenedione 
ingestion in 30-56 year old men. Our results suggest that ingesting 100 mg androstenedione 
three times daily is unlikely to provide a desirable hormonal milieu for promoting increases 
in muscle size, and may lead to untoward health effects. 
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Tables and Figures 
Table 1 Anthropometric data for subjects 
PL ASD 
30 year olds 40 year olds 50 year olds 30 year olds 40 year olds 50 year olds 
(n=10) (n=10) (n=8) (n=10) (n=10) (n=7) 
Age (y) 
34+1 44+1 53±1 33 + 1 43 + 1 52 + 1 
Height (cm) 
181+4 182+2 174+3 180+3 180+2 177+2 
Body Mass (kg) 
96+6 101 + 10 87+7 84+5 91+3 87+5 
Body Mass Index (kg/m2) 
29 ±2 30+2 29+2 26+1 28+1 28+2 
Values are expressed as means + SE. 
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Table 2 Serum lipid concentrations during 4 weeks of supplementation 
PL ASD 
30 year olds 40 year olds 50 year olds 30 year olds 40 year olds 50 year olds 
Week (n=10) (n=10) (n=8) (n=10) (n=10) (n=7) 
Total-C 
0 4.31+0.51 4.90±0.41 5.39±0.29 4.75±0.19 4.76±0.26 5.79±0.42 
1 4.56±0.29 5.15±0.41 5.49+0.41 4.56±0.20 4.90±0.35 5.46±0.32 
2 4.69+0.25 5.24±0.49 5.49±0.35 4.65±0.22 4.88±0.24 5.48±0.44 
3 4.41 ±0.31 5.04±0.44 5.72±0.35 4.29±0.25 4.80±0.23 5.32±0.38 
4 4.54+0.30 4.85 ±0.43 5.50±0.23 4.49±0.27 4.66±0.26 5.22±0.35 
HDL-C 
0 O.95+O.O6 0.98±0.11 1.23±0.13 1.21 ±0.09 0.99±0.07 I.09±0.I2 
1 0.94+0.06 0.99±0.10 1.21±0.12 1.04±0.06* 0.90±0.05* 0.97±0.09* 
2 O.9O+O.O6 0.99±0.09 1.22±0.13 1.04±0.05* 0.94±0.05* 1.01±0.10* 
3 0.93 ±0.07 1.00±0.09 1.27±0.12 1.02±0.05* 0.88±0.05* 1.00±0.09* 
4 0.96±0.07 0.99±0.10 1.21±0.12 1.05 ±0.04* 0.91 ±0.05* 1.01 ±0.09* 
LDL-C 
0 3.02 ±0.23 3.14±0.3 3.33±0.27 2.89±0.17 2.93±0.23 3.69±0.21 
1 2.79±0.28 3.43 ±0.34 3.44±0.39 2.96±0.19 3.32±0.31 3.72±0.21 
2 3.04±0.22 3.46±0.47 3.49±0.33 3.02±0.23 3.Î3+O.24 3.84±0.41 
3 2.68±0.25 3.36±0.43 3.67±0.28 2.15+022 3.12±0.19 3.55±0.30 
4 2.76±0.20 3.08±0.30 3.58±0.23 2.81 ±0.23 3.04±0.19 3.41 ±0.25 
Values are expressed as means ± SE (mmol/L). * Significantly different from week 0 
(Main treatment effect; P<0.05) 
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Figure 1. 
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Serum androstenedione concentrations during four weeks of nutritional 
supplementation. 
* = significantly different from week 0 (Main group effect, P < 0.05). f = 40 and 50 year 
olds different from 30 year olds (Main group effect, P < 0.05). 
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Serum total testosterone concentrations during four weeks of nutritional 
supplementation. 
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Serum free testosterone concentrations during four weeks of nutritional 
supplementation. 
* = significantly different from week 0 (Main group effect, P < 0.05). f - 50 year olds 
different from 30 year olds (Main effect, P < 0.05). 
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Serum dihydrotestosterone concentrations during four weeks of nutritional 
supplementation. 
* = significantly different from week 0 (Main group effect, P < 0.05). f = 40 and 50 year 
olds different from 30 year olds (Main effect, P < 0.05). 
66 
0.45 i 
0.35 
0.25 
0.15 J 
0.45 
0.35 
0.25 
0.15 
0.45 
0.35 
0.25 
0.15 J 
30 year olds 
#--# PL 
0-0 ASD 
40 year olds 
- -4- —i 
50 year olds 
^  f — •  
T~ 
2 
T 
3 
Week 
Figure 5. Serum estradiol concentrations during four weeks of nutritional 
supplementation. 
* == 
= significantly different from week 0 (Main effect, P < 0.05) 
67 
8 
7 
6 
5 
4 -
3 
2 
1 -
8 
E 7 Ô) 6 • c 
< 5 • 
CO 
Q. 4 -
E 3 -3 
O 2 -
CO 1 -
8 • 
7 -
6 -
5 -
4 -
3 -
2 -
1 -
30 year olds 
O—O 
40 year olds 
50 year olds 
* * H "K 4—$• * -5 ^ 
i 1 1 1 i 
0 12 3 4 
Week 
Figure 6. Serum PSA concentrations during four weeks of nutritional supplementation. 
* = significantly different from all other age and treatment groups)main group effect, 
P<0.05). 
68 
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A paper published in the International Journal for Vitamin and Nutrition Research 
71:293-301,2001. 
Gregory A. Brown1,3, Matthew D. Vukovich2'5, Emily R. Martini1,5, Marian L. Kohut1,5, 
Warren D. Franke1'5, David A. Jackson1,5, and Douglas S. King1'4 
'Exercise Biochemistry Laboratory, Department of Health and Human Performance, Iowa 
State University, Ames LA 
2Human Performance Laboratory, South Dakota State University Department of HPER, 
Brookings, SD 
^Graduate student, primary researcher and author. 
4Major Professor, professor, and corresponding author 
Contributed significantly to sample collection and overall research completion 
Abstract 
The effectiveness of a nutritional supplement designed to enhance serum testosterone 
concentrations and prevent the formation of dihydrotestosterone and estrogens from the 
ingested androgens was investigated in healthy 30 to 59 year old men. Subjects were 
randomly assigned to consume DION (300-mg androstenedione, 150-mg 
dehydroepiandrosterone, 540-mg saw palmetto, 300-mg indole-3-carbinol, 625-mg chrysin, 
and 750-mg Tribulus terrestris per day; n=28) or placebo (n=27) for 28 days. Serum free 
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testosterone, total testosterone, androstenedione, dihydrotestosterone, estradiol, prostate 
specific antigen, and lipid concentrations were measured before and throughout the 4-week 
supplementation period. Serum concentrations of total testosterone and prostate specific 
antigen were unchanged by supplementation. DION increased (P<0.05) serum 
androstenedione (342%), free testosterone (38%), dihydrotestosterone (71%), and estradiol 
(103%) concentrations. Serum HDL-C concentrations were reduced by 5.0 mg/dl in DION 
(P<0.05). Increases in serum free testosterone (r2 = 0.01), androstenedione (r2= 0.01), 
dihydrotestosterone (r2= 0.03), or estradiol (r2= 0.07) concentrations in DION were not 
related to age. While the ingestion of androstenedione combined with herbal products 
increases serum free testosterone concentrations in older men, these herbal products do not 
prevent the conversion of ingested androstenedione to estradiol and dihydrotestosterone. 
Introduction 
Androstenedione ingestion in dosages of 100-300 mg day"' in young men does not 
chronically increase serum free or total testosterone concentrations, but does increase serum 
estrogen concentrations [1-4]. In contrast, we recently observed 100 mg androstenedione 
taken three times daily in older (30-56 y) men for 28 days produces a modest (45%) increase 
in serum free testosterone and more substantial elevations in serum dihydrotestosterone 
(83%), and estradiol (68%) [5]. Although these hormonal increases were significant, the 
resultant concentrations remained within the normal physiological range. 
Recently, it has been suggested that certain herbal extracts may prevent the 
conversion of androgens to dihydrotestosterone (DHT) and estrogens, and increase serum 
testosterone concentrations. Although it has been advertised that an extract from Tribulus 
terrestris increases serum luteinizing hormone and testosterone concentrations, there are no 
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published studies confirming this claim. Indole-3-carbinol, an extract from cruciferous 
vegetables, has been shown to enhance oxidative metabolism and excretion of estrogens in 
middle-aged men and women [6]. Chrysin, a flavonoid from Passiflora caerulea, inhibits the 
aromatization of androgens to estrogens in vitro [7]. Saw palmetto decreases the in vitro 5a 
reduction of androgens [8]. It has been speculated that the ingestion of these extracts with 
DHEA and androstenedione may prevent 5a-reduction and aromatization, limiting the fate of 
the ingested androgens to the 170 hydroxysteroid dehydrogenase (17P-HSD) pathway [9]. 
However, we have observed that when young men ingest a supplement (DION) containing 
androstenedione, dehydroepiandrosterone (DHEA), indole-3-carbinol, chrysin, saw palmetto, 
and Tribulus terrestris the hormonal response is not different from ingesting androstenedione 
alone [10]. Since we have previously observed that the testosterone response to 
androstenedione ingestion is different in older and younger men [1,5], we tested the 
hypothesis that inclusion of these herbal extracts during chronic androstenedione and DHEA 
supplementation alters the fate of the ingested androgens in older men. 
Methods 
Subjects 
Fifty-six healthy men between the ages of 30 and 59 were recruited from the 
university and local community for this project. All subjects signed an informed consent and 
completed a thorough written medical history to remove any subjects with known chronic 
disease. Subjects were questioned to ensure they had no current or previous use of 
nutritional supplements prior to participating in this study, which was approved by the Iowa 
State University human subjects review board. 
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Blood Sample Collection and Analysis 
Fasting blood samples were collected between 6:30 and 8:00 a.m. at the same time 
each week. Five minutes after insertion of a catheter into an antecubital vein, blood samples 
were obtained without stasis from supine subjects. Blood samples were immediately placed 
in an ice bath until centrifugation and serum separation. A commercial laboratory performed 
blood chemistry analysis of liver function enzymes, serum albumin, proteins, globulins, and 
lipid concentrations (Quest Diagnostics, Wood Dale, IL). Serum concentrations of estradiol, 
free testosterone, total testosterone, and androstenedione were measured in duplicate via 
commercial radioimmunoassay kits (Diagnostic Products Corp, Los Angeles, CA and 
Diagnostic Systems Laboratory, Webster TX). Commercially available enzyme-linked 
immunosorbent assays were used to measure serum concentrations of prostate specific 
antigen (PSA; Bio-Clin, Inc, St. Louis, MO) and dihydrotestosterone (DHT; Immuno 
Biological Laboratories, Hamburg, Germany). The intra assay coefficients of variation for 
total testosterone, free testosterone, estradiol, androstenedione, DHT and PSA were 6.1%, 
7.2%, 6.6%, 5.8%, 3.2% and 6.6%, respectively. According to the information supplied by 
the assay manufacturers, there was no detectable cross reactivity between androstenedione 
and free testosterone, total testosterone, DHT, or estradiol. 
Diet and Activity 
Subjects were instructed to maintain normal diet and activity patterns throughout the 
study. Subjects were given verbal and written instructions on the reporting of daily physical 
activity and dietary intake and maintained diet, medication, and exercise records for the 2 
days prior to each blood sampling. The dietary records were collected prior to weekly blood 
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sampling and analyzed using commercial software (Nutritionist 4, N-Squared computing, 
San Bruno CA). 
Supplementation 
Using a double blind counter balanced design subjects were randomly assigned to 
consume capsules containing rice flour placebo (PL) or DION that contained daily doses of 
300 mg androstenedione, 150 mg DHEA, 540 mg saw palmetto, 300 mg indole-3-carbinol, 
625 mg chrysin, and 750 mg Tribulus terrestris. Subjects were instructed to consume the 
supplements in equal doses before 9:00 am, at 3:00 pm, and before bedtime. A supplier of 
nutritional supplements (Experimental and Applied Sciences, Golden, CO) provided the 
DION and an independent laboratory (Integrated Biomolecule, Tucson, AZ) verified purity 
and content of the supplements with high performance liquid chromatography (HPLC). 
Compliance was monitored through written records of supplementation and the return of 
empty supplement containers at the completion of the study. 
Calculations and Statistics 
To facilitate data presentation, subjects were stratified into age groups representing 
the fourth (30 year olds), fifth (40 year olds), and sixth (50 year olds) decades. Data were 
analyzed using commercial software (SPSS Inc, Chicago, IL). Statistical analyses were 
performed using a 3 factor (Week by Treatment by Age group) repeated measures analysis of 
variance (ANOVA). Because basal serum hormone concentrations may alter the endocrine 
response to androgen supplementation, analysis of covariance (ANCOVA) was performed 
using basal hormone concentrations as the covariate. Specific mean differences (P < 0.05) 
were analyzed using a Student Newman-Keuls multiple comparison test. Analysis of age 
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related effects of supplementation were conducted through tests of simple linear regression. 
Data are presented throughout as means ± SE. 
Results 
Subjects 
Subjects came from a variety of occupations and had varied physical activity levels. 
Nine subjects in DION and 10 in PL reported regular participation in aerobic activity while 
resistance exercise was reported in 5 subjects in DION and 6 in PL. Physical activity was 
reported in 55% of the 30 and 40 year olds and in 20% of the 50 year olds. No changes in 
physical activity patterns were reported during the course of the investigation. No 
differences in height, body mass, or body mass index (BMI) were found between treatment 
and age groups (Table 1), and body mass and BMI did not change in any age or treatment 
group during the experimental period. One 50-year-old subject in the placebo group was 
diagnosed with non-insulin dependent diabetes mellitus during the study and informed of the 
condition; his data have been excluded from all analyses. This project was part of a larger 
study and the data for the placebo group have been reported elsewhere [5]. 
Hormonal Response to Supplementation 
The results of the ANCOVA revealed no significant effect of basal serum hormone 
concentrations on the endocrine response to DION ingestion. Since the results of the 
statistical analysis were not different between the ANOVA and ANCOVA, the actual means 
rather than the adjusted means from the ANCOVA, are presented throughout the text 
Serum total testosterone concentrations did not differ significantly between the three 
age groups, and were not altered during the 4 weeks of supplementation in any age or 
treatment group (Figure 1). 
Basal serum free testosterone concentrations were significantly related to age 
(r2=0.23), and were lower in the 50 year olds than the 30 year olds (Figure 2; P<0.05). There 
was a significant (P < 0.05) Treatment-by-Week effect, but no Age-by-Week-by-Treatment 
effect. For all ages combined, ingestion of DION resulted in a 38% increase (P<0.05) in 
serum free testosterone concentrations during weeks 1-4. There was no relationship between 
the observed change in serum free testosterone concentrations and age (r2=0.01). 
Basal serum androstenedione concentrations were higher in the 30 year olds than in 
the 40 or 50 year olds (Figure 3; P < 0.05). There was a significant (P < 0.05) Treatment-by-
Week effect, but no Age-by-Week-by-Treatment effect. For all ages are combined, ingestion 
of DION resulted in a 342% increase in serum androstenedione concentrations during weeks 
1-4. There was no relationship between the observed change in serum androstenedione 
concentrations and age (r2=0.01). Serum androstenedione concentrations were increased 
above normal expected values in response to DION ingestion. 
Baseline serum DHT concentrations were higher in the 30 year olds than in the 40 or 
50 year olds (P<0.05; Figure 4). There was a significant (P < 0.05) Treatment-by-Week 
effect, but no Age-by-Week-by-Treatment effect. For all ages combined, ingestion of DION 
resulted in a 71% increase in serum DHT concentrations during weeks 1-4. There was no 
relationship between the observed change in serum DHT concentrations and age (r2=0.047). 
Basal serum estradiol concentrations were not different between age or treatment 
group (Figure 5). There was a significant (P < 0.05) Treatment-by-Week effect, but no Age-
by-Week-by-Treatment effect. For all ages combined, ingestion of DION resulted in a 103% 
increase in serum estradiol concentrations during weeks 1 -4. No relationship was observed 
between the mean increase in serum estradiol concentrations during weeks 1- 4 and age 
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(1^=0.012) or body mass index (r2=0.071). The change in serum estradiol concentrations was 
not different between physically active and inactive subjects. 
For all ages combined the ratio of total testosterone (nmol l"1) to estradiol (nmolT1) 
decreased (P<0.05) during weeks 1-4 in DION (134 ± 15 vs. 65 ± 5) and remained stable in 
PL (106 ± 9 vs. 113 ± 9). Similarly, for all ages combined, the ratio of free testosterone 
(pmolT1) to estradiol (pmol l"1) decreased (P0.05) during weeks 1-4 in DION (0.42 ± 0.04 
vs. 0.29 ± 0.02) and did not change in PL (0.37 ± 0.03 vs. 0.39 ± 0.03). 
Serum PSA concentrations were unaffected by age or supplementation (Figure 6). 
The mean serum PSA concentrations throughout the 4 weeks of supplementation for all 
treatment groups combined were 2.1 ng ml"', 2.6 ng ml"' and 2.5 ng ml"' for the 30,40, and 
50 year olds, respectively. 
Serum Lipid Response 
Basal serum lipid concentrations were not different between age or treatment groups 
(Table 2). For all ages combined, ingestion of DION resulted in 8% reductions in serum 
HDL-C during weeks 1-4 (P < 0.05; Treatment-by-Week effect). The observed decrease in 
serum HDL-C concentrations was not related to age (r2=0.001), but was significantly related 
to pre-supplementation HDL-C concentrations (r2=0.284). Serum low-density lipoprotein 
cholesterol (LDL-C) and total cholesterol (Total-C) concentrations were not altered by age or 
supplementation. 
Blood Chemistry Response 
Serum concentrations of gamma-glutamyltransferase, aspartate aminotransferase and 
alanine aminotransferase remained unchanged throughout the 4-week supplementation period 
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and were not affected by age (data not shown). There was also no age or supplement related 
change in serum concentrations of protein, albumin, or globulin (data not shown). 
Dietary Analysis 
There were no significant differences in dietary macronutrient intake throughout the 
study for either age or treatment group (Table 3). There were also no age or group 
differences observed for alcohol, saturated fat, monounsaturated fat, polyunsaturated fat, or 
cholesterol intake (data not shown). Subjects reported no use of prescription medications and 
only occasional use of over the counter medications such as analgesics. 
Discussion 
Two novel findings of the present research are 1) chronic DION ingestion increases 
serum free testosterone concentrations in 30-59 year old men and 2) the ingestion of saw 
palmetto in the presence of exogenous androgens does not prevent the 5a-reduction of 
ingested androgens. The present results also extend the previously observed findings in 
young men [10] that ingestion of DION does not prevent aromatization of ingested 
androstenedione or increase serum total testosterone concentrations in older men. 
Although androstenedione can be enzymatically converted to testosterone [11-13], 
daily doses of 100-300 mg androstenedione do not chronically increase serum total 
testosterone concentrations in young [1-3] or older men [5,14]. The present results suggest 
that ingestion of DION, which contains androstenedione, also does not increase serum total 
testosterone concentrations in men between 30 and 59 years or age. In contrast, Leder et al. 
[3] observed that serum total testosterone concentrations increased -34% following a single 
300-mg androstenedione dose. These authors observed that serum total testosterone 
concentrations returned to baseline within -4-6 hours, suggesting that daily doses of300-mg 
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androstenedione or less are unlikely to produce chronic elevations in serum total testosterone 
concentrations. 
Ingestion of androstenedione alone [1,4], or formulated as DION [10], does not 
increase serum free testosterone concentrations in 19-24 year old men. In contrast, DION 
ingestion increases serum free testosterone concentrations in 30-59 year old men. The 
elevations in serum free testosterone concentrations in DION in the current study confirm our 
previous observations of elevated serum free testosterone concentrations with chronic 
androstenedione ingestion in older men [5]. Consistent with the previously observed age 
related declines in serum free testosterone concentrations [15-18], the serum free testosterone 
concentrations in the current older subjects were lower than in the younger subjects in our 
previous research [10], suggesting that age and basal serum free testosterone concentrations 
may affect the free testosterone response to androstenedione intake. In addition, the large 
degree of unexplained individual variability in the serum testosterone response to 
androstenedione ingestion in young men [3] suggests that other, unknown factor(s) may 
influence the testosterone response to androstenedione ingestion. 
The use of weak androgens to increase serum testosterone concentrations is based on 
the findings that DHEA [19, 20] and androstenedione [19] ingestion increase serum 
testosterone concentrations in women. Since women have much lower serum testosterone 
concentrations than men, and since serum free testosterone concentrations decline in aging 
men [15-18], it has been hypothesized that DHEA ingestion may enhance serum free 
testosterone concentrations in older men. However, the ingestion of DHEA does not appear 
to increase serum free or total testosterone concentrations in men up to 70 years old [14, 20 -
23]. Therefore, it is likely that the increase in serum free testosterone concentrations in the 
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present study was a consequence of the conversion of androstenedione, rather than DHEA, to 
testosterone. 
In spite of the inclusion of chrysin, indole-3-carbinol, saw palmetto, and Tribulus 
terrestris the hormonal response to DION ingestion did not differ from that observed with 
androstenedione [5] ingestion. While chrysin [7] inhibits the aromatization of androgens and 
indole-3-carbinol increases the hydroxylation and excretion of estrogens [6], these 
compounds do not appear to prevent the in vivo increase in serum estrogen concentrations 
after androstenedione ingestion. Although saw palmetto has been observed in vitro to impair 
the 5a reduction of endogenous androgens to DHT [8], the increase in serum DHT with 
DION ingestion is comparable to the increase observed with androstenedione ingestion alone 
[5], suggesting that saw palmetto does not reduce the in vivo conversion of ingested 
androgens to DHT. The serum testosterone response to DION [10, present results] is 
remarkably similar to previous observations made with only androstenedione ingestion [1,5], 
suggesting that the inclusion of Tribulus terrestris also does not alter the serum testosterone 
response to ingesting androstenedione. Taken together, these results suggest that the 
inclusion of indole-3-carbinol, chrysin, saw palmetto, and Tribulus terrestris in conjunction 
with androstenedione does not alter the hormonal response to androstenedione ingestion. 
DION is designed to enhance serum testosterone concentrations and enhance the 
adaptations to resistance training. Exogenous testosterone administration resulting in large 
increases in serum free and total testosterone concentrations increases muscle strength and 
size in young [24] and older [25] men. However, the increases in serum testosterone 
concentrations typically required to increase muscle size and strength [25] are -4-10 fold 
larger than the currently observed increases in serum free testosterone [24]. DION does not 
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enhance the adaptations to resistance training nor increase serum testosterone concentrations 
in young men [ 10]. Whether an anabolic effect is seen with the 38-45% increases in serum 
free testosterone concentrations associated with androstenedione alone [5] or formulated as 
DION [present results] in older men is unknown. 
Physiologic levels of estradiol stimulate HDL-C synthesis in normal men [26], and 
elevated serum estrogens can have positive effects on vascular reactivity and serum lipid 
concentrations [27]. However, in spite of the elevated serum estradiol concentrations 
presently observed, serum HDL-C concentrations decreased with DION ingestion. Phillips 
et al. [28] observed that -20% elevations in serum estradiol concentrations in men are 
associated with the occurrence of myocardial infarction. There is also a risk for 
gynecomastia associated with elevated serum estrogen levels [29]. While it is unlikely that 
the increased serum estradiol concentrations in the present study had any long-term effects 
on health, the effects of increased serum estradiol levels subsequent to long term DION 
ingestion are unknown. 
Ballantyne et al. [4] observed that androstenedione ingestion augments the increase in 
serum estrogens observed immediately after resistance exercise. However, in the current 
study blood samples were obtained at least 8-10 h after any physical activity and the 
increased serum estradiol concentrations in response to DION did not differ between 
physically active and inactive subjects. These data suggest that physical activity does not 
alter the chronic increase in serum estradiol concentrations associated with androstenedione 
ingestion. 
Elevated serum androstenedione concentrations and a 150 % reduction of the serum 
testosterone to androstenedione ratio have been observed in patients with pancreatic cancer 
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[30]. The increase in serum androstenedione and 135% decrease in the testosterone to 
androstenedione ratio observed during ingestion of DION are suggestive of an elevated risk 
for pancreatic carcinoma. 
The effect of weak androgen ingestion on prostate health is of particular concern in 
the aging male. We have previously observed that 300 mg d"1 androstenedione ingestion 
does not alter serum PSA concentrations in healthy men [5], The present findings confirm 
these findings, and suggest that chrysin, indole-3-carbinol, saw palmetto and Tribulus 
terrestris also do not alter serum PSA concentrations. While serum PSA concentrations were 
not altered during the course of this study, 30% of males with prostatic tumors demonstrate 
normal serum PSA concentrations [31]. In addition, in dogs benign prostatic hypertrophy 
has been induced with -100% increases in serum estradiol and DHT concentrations [32]. 
Therefore, the 103% increase in serum estradiol and 71% increase in serum DHT 
concentrations suggest that the potential risk of impaired prostate function with long term 
DION use should not be disregarded. 
In conclusion, the ingestion of 300-mg day-1 androstenedione combined with herbal 
extracts containing aromatase and 5a-reductase inhibitors does not increase serum total 
testosterone or PSA concentrations in 30-59 year old men, but does increase serum 
concentrations of free testosterone, estradiol, androstenedione, and DHT. Thus, the addition 
of these herbal extracts to androgenic compounds does not appear to mitigate the serum 
hormonal and lipid response to androgen ingestion. The changes in serum hormone and lipid 
concentrations associated with androgen ingestion suggest possible negative health 
consequences with long-term use of these products. 
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Table and Figures 
Table 1. Anthropometric data 
30 year olds 40 year olds 50 year olds 
PL DION PL DION PL DION 
(n=10) (n=10) (n= 10) (n=10) (n=7) (n=8) 
Age (y) 34+1 33 + 1 44+1 44+1 53±1 53 + 1 
Height (cm) 181 ±4 179+2 182±2 180+3 Î74+3 175+3 
Body Mass (kg) 96±6 89+6 10I±10 88+4 87+7 82+3 
BMI (kg/m2) 29±2 28+2 30+2 27+1 29+2 27+1 
Data are Means + SE. 
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Table 2. Serum cholesterol concentrations during four weeks of supplementation 
30's 
PL DION 
Week (n=10) (n=10) 
40's 
PL DION 
(n=10) (n=10) 
50's 
PL DION 
(n=7) (n=8) 
HDL-C 0 0.95+0.06 1.07+0.07 0.98+0.11 1.00+0.05 1.23+0.13 1.04+0.07 
1 0.94+0.06 1.00+0.06* 0.99+0.10 0.94+0.07* 1.21+0.13 0.93+0.05* 
2 0.90+0.06 0.92+0.06* 0.99+0.09 0.85+0.05* 1.22+0.13 0.87+0.05* 
3 0.93+0.07 0.91+0.04* 1.00+0.09 0.87+0.06* 1.27+0.13 0.90+0.05* 
4 0.96+0.07 0.93 +0.06* 0.99 +0.10 0.89 +0.06* 1.21+0.13 0.87+0.05* 
LDL-C 0 3.02+0.23 3.31+0.19 3.14+0.30 3.19+0.24 3.33+0.27 3.05+0.16 
1 2.79+0.28 3.30+0.20 3.43+0.34 3.13+0.20 3.44+0.39 3.02+0.21 
2 3.04+0.22 3.14+0.18 3.46+0.47 3.05+0.24 3.49+0.33 2.89+0.20 
3 2.68+0.25 3.05±0.17 3.36+O.43 3.04±0.20 3.67±0.28 3.00±0.19 
4 2.76+0.20 2.94+0.19 3.08+0.30 2.87+0.15 3.58+0.23 3.05+0.20 
Total-C 0 4.31+0.51 4.99+0.20 4.90+0.41 4.99+0.39 5.39+0.29 4.69+0.50 
1 4.56±0.29 4.95±0.27 5.Î5+O.4Î 4.95±0.35 5.49±0.41 4.65±0.66 
2 4.69+0.25 4.69+0.17 5.24+0.49 4.76+0.34 5.49+0.35 4.54+0.59 
3 4.41+0.31 4.25+0.49 5.04+0.44 4.54+0.21 5.72+0.35 4.58+0.57 
4 4.54±0.30 4.64 +0.29 4.85 +0.43 4.43 +0.15 5.50+0.23 4.79 +0.66 
Data are Means ± SE. Units are mmol/L. * Significantly different from week 0 for DION 
(Treatment-by-Week effect, P < 0.05) 
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Table 3. Daily macronutrient intake during 4 weeks of supplementation 
Week 
30's 
PL DION 
(n=10) (n=10) 
40's 
PL DION 
(n=10) (n=10) 
50's 
PL DION 
(n=7) (n=8) 
KJ10 10.0+0.7 9.7+0.5 9.6+0.8 9.5+1.1 8.5+1.3 9.5+0.8 
9.9+1.0 9.6+0.6 10.0+1.2 8.6+0.8 8.7+1.2 8.8+1.0 
10.7+0.8 9.2+0.6 10.8+1.1 9.1 + 1.2 8.8+0.8 8.9+0.7 
9.9+0.810.1+0.6 8.8+1.1 8.4+1.2 8.6+0.7 8.0+1.3 
CHO(g) 
4 
0 
1 
2 
9.8+0.7 9.8+0.3 9.8+0.9 9.4+1.0 7.1 + 1.0 8.2+0.8 
331+29 343+27 330+29 314+42 286+71 332+41 
339+42 303 + 28 338+47 308+34 296+42 341 + 39 
366+34 291+25 322+34 305+47 298+46 321+25 
Fat(g) 
3 
4 
0 
1 
2 
346+21 337+24 290+43 298+52 288+37 276+38 
340+26 308+21 348+40 341+35 217+17 291+30 
78+8 65+6 
77+10 71 + 10 
83 + 10 61 + 5 
68+10 72+10 
72+10 56+9 
93+16 69+12 
51+9 63 + 5 
58+12 51 + 9 
59+5 57+12 
70+12 70+8 62+6 62+9 60+6 61+14 
76+12 71+9 68+1 81 + 15 56+12 56+10 
Data are Means + SE. 
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year olds significantly different from 30 year olds at baseline (Age-by-Week effect, P < 
0.05). 
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Figure 3. Serum androstenedione concentrations during four weeks of nutritional 
supplementation. 
*significantly different from week 0 for DION (Treatment-by-Week effect, P < 0.05); X 30 
year olds significantly different from 40 and 50 year olds at baseline (Age-by-Week effect, P 
< 0.05). 
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Figure 4. Serum dihydrotestosterone concentrations during four weeks of nutritional 
supplementation. 
*significantly different from week 0 for DION (Treatment-by-Week effect, P < 0.05); $ 30 
year olds significantly different from 40 and 50 year olds at baseline (Age-by-Week effect, P 
< 0.05). 
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Figure 5. Serum estradiol concentrations during four weeks of nutritional 
supplementation. 
* significantly different from week 0 for DION (Treatment-by-Week effect, P < 0.05). 
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Serum prostate specific antigen concentrations during four weeks of 
nutritional supplementation. 
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Abstract 
Objective. The effectiveness of an androgenic nutritional supplement designed to enhance 
serum testosterone concentrations and prevent the formation of dihydrotestosterone and 
estrogens was investigated in healthy 30 to 58 year old men. Design. Subjects were 
randomly assigned to consume a nutritional supplement (AND-HB) containing 300-mg 
androstenediol, 480-mg saw palmetto, 450-mg indole-3-carbinol, 300-mg chrysin, 1,500 mg 
gamma-linolenic acid, and 1,350-mg Tribulus terrestris per day (n=28), or placebo (n=27) for 
28 days. Subjects were stratified into age groups to represent the fourth (30 yr olds, n=20), 
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fifth (40 yr olds, n=20) and sixth (50 yr olds, n=16) decades of life. Measurements. Serum 
free testosterone, total testosterone, androstenedione, dihydrotestosterone, estradiol, prostate 
specific antigen, and lipid concentrations were measured before supplementation and weekly 
for 4 weeks. Results. Basal serum total testosterone, estradiol, and prostate specific antigen 
(PSA) concentrations were not different between age groups. Basal serum free testosterone 
concentrations were higher (P<0.05) in the 30- (70.5 ±3.6 pmol/L) than in the 50 year olds 
(50.8 ± 4.5 pmol/L). Basal serum androstenedione and dihydrotestosterone (DHT) 
concentrations were significantly higher in the 30- (for androstenedione and DHT 
respectively; 10.4 ± 0.6 nmol/L and 2198.2 ± 166.5 pmol/L) than in the 40- (6.8 ± 0.5 
nmol/L and 1736.8 ± 152.0 pmol/L) or 50 year olds (6.0 ± 0.7 nmol/L and 1983.7 ± 147.8 
pmol/L). Basal serum hormone concentrations did not differ between the treatment groups. 
Serum concentrations of total testosterone and PSA were unchanged by supplementation. 
Ingestion of AND-HB resulted in increased (P<0.05) serum androstenedione ( 174%), free 
testosterone (37%), DHT (57%), and estradiol (86%) throughout the 4 weeks. There was no 
relationship between the increases in serum free testosterone, androstenedione, DHT, or 
estradiol and age (r2 = 0.08,0.03,0.05 and 0.02, respectively). Serum HDL-C concentrations 
were reduced (P<0.05) by 0.14 mmolT1 in AND-HB. Conclusions. These data indicate that 
ingestion of androstenediol combined with herbal products does not prevent the formation of 
estradiol and dihydrotestosterone. 
Introduction 
Androstenediol (4-androstene-3p, 17(3-diol) is an androgenic precursor to testosterone [1,2]. 
Advertisements claim that ingesting androstenediol increases serum testosterone 
concentrations and augments the gains in muscle mass and strength associated with 
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resistance training. However, in men, serum testosterone concentrations are not increased 
within 90 minutes of a single 200 mg dose [3] or when blood is sampled -12 h after ingesting 
100 mg [4] androstenediol but serum estradiol concentrations are increased -12 h after 
intake. 
Several herbal extracts have been demonstrated to alter steroid metabolism and may 
change the endocrine response to androstenediol intake. Saw palmetto [5] and gamma 
linolenic acid (yLA) [6] inhibit the in vitro 5a reduction of androgens to dihydrotestosterone 
(DHT). Chiysin has been shown to impair aromatization in vitro [7] and indole-3-carbinol 
has been shown to enhance the urinary clearance of estrogens in vivo [8]. Tribulus terrestris 
is purported to increase testosterone concentrations by increasing serum luteinizing hormone 
concentrations, although this claim has not been verified. While androstenediol ingestion 
alone does not appear to alter serum testosterone concentrations [3,4], inclusion of these 
herbal extracts with androstenediol may prevent the breakdown of androstenediol to 
estrogens or dihydrotestosterone resulting in increased serum testosterone concentrations. 
Therefore, the purpose of this project was to determine whether chronic ingestion of a 
nutritional supplement (AND-HB) that combines androstenediol, saw palmetto, yLA, indole-
3-carbinol, chrysin, and Tribulus terrestris increases serum testosterone concentrations while 
preventing increased serum estradiol and DHT concentrations in healthy men. 
Methods 
Subjects and General Design 
Fifty-six healthy men (30 - 58 y) ingested either a rice flour placebo (PL) or AND-
HB for four weeks. Blood samples were collected each week for the measurement of serum 
hormone concentrations and blood chemistry. Prior to participating in this project all 
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subjects provided informed consent, were questioned to ensure they were not currently using 
nutritional supplements, and completed a written medical history to eliminate subjects with a 
known chronic disease. The human subjects review committee at Iowa State University 
provided approval for this project. 
Supplementation 
Subjects were randomly assigned in a double blind, counter balanced manner to 
consume unmarked capsules containing either PL or AND-HB. Subjects were instructed to 
consume the supplements in equal doses t.i.d. (before 0900 h, at 1500 h, and before bedtime). 
AND-HB contained daily doses of 300 mg androstenediol, 480 mg saw palmetto, 450 mg 
indole-3-carbinol, 300 mg chrysin, 1,500 mg yLA, and 1,350 mg Tribulus terrestris. The 
capsules were provided by a supplier of nutritional supplements (Experimental and Applied 
Sciences, Golden, CO) and were assayed for content and purity (-99%) using high-
performance liquid chromatography (HPL-C) by an independent laboratory (Integrated 
Biomolecule, Tucson, AZ). Subject compliance to the supplementation regime was assessed 
through written records and the return of supplement containers at the conclusion of the 
study. 
Diet and Activity 
Subjects were instructed to maintain their normal diet and activity pattern throughout 
the course of the study and also record their diet and activity for the 2 d prior to each blood 
sampling. Dietary composition was analyzed using commercial software (Nutritionist 4, N-
Squared computing, San Bruno, CA). 
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Blood Sample Collection and Analysis 
Fasting blood samples were collected between 0630 and 0800 at baseline and once 
per week, -8-10 hours after supplement ingestion, on the same day each week, for 28 days. 
Blood samples (-20 ml) were collected without stasis from an antecubital vein and 
immediately placed into an ice bath until centrifugation and serum separation. Blood 
samples were analyzed for liver function enzyme, lipid, and protein composition by a 
commercial laboratory (Quest Diagnostics, Inc., Wood Dale, IL). Serum concentrations of 
total testosterone, free testosterone, androstenedione, and estradiol were measured via 
commercial tracer analog radioimmunoassay kits (Diagnostic Products Corp, Los Angeles, 
CA; and Diagnostic Systems Laboratory, Webster, TX). Serum DHT and prostate specific 
antigen (PSA) concentrations were measured with commercially available enzyme-linked 
immunosorbent assay (ELISA; Bio-Clin, Inc, St. Louis, MO; Immuno-Biological 
Laboratories, Hamburg, Germany). The samples for each subject were analyzed in duplicate 
within the same assay and the intra-assay coefficients of variation for total testosterone, free 
testosterone, estradiol, androstenedione, DHT and PSA were 6.1%, 7.2%, 6.6%, 5.8%, 3.2% 
and 6.6%, respectively. According to the manufacturers of the RIA and ELISA kits, there is 
no detectable cross reactivity of the assays for androstenediol, androstenedione, DHT, 
estradiol or testosterone. 
Calculations and Statistics 
To facilitate data analysis and presentation, subjects were grouped by age to represent 
the fourth (30 yr olds, n=20), fifth (40 yr olds, n=20) and sixth (50 yr olds, n=16) decades of 
life. Statistical analyses of the data were performed using a 3 factor (Week by Treatment by 
Age group) repeated measures analysis of variance (ANOVA) with commercial software 
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(SPSS Inc, Chicago, IL). Specific mean differences (P < 0.05) were identified using Student 
Newman-Keuls post hoc comparisons. Because basal serum hormone concentrations may 
alter the endocrine response to androstenediol supplementation, analysis of covariance 
(ANCOVA) was performed using basal hormone concentrations as the covariate. 
Relationships between the effects of supplementation and age were analyzed using simple 
linear regression. The percent change in serum analytes was calculated as the mean change 
from baseline for all subjects during weeks 1-4. Data are presented throughout as means ± 
SE. 
Results 
Subjects 
Subjects came from a wide variety of occupations and physical activity levels. No 
changes in physical activity patterns were reported during the course of the investigation. 
Twelve subjects in AND-HB and 10 in PL reported regular participation in aerobic activity 
such as running and basketball while resistance exercise was reported in 4 subjects in AND-
HB and 6 in PL. No differences or changes in height, body mass, or body mass index (BMI) 
were found for any treatment or age group (Table 1). One 50-year-old subject in the placebo 
group was diagnosed with non-insulin dependent diabetes mellitus during the study, 
informed of the condition, and his data have been excluded from all analysis. This project 
was part of a larger study, and the data for the placebo group has been reported elsewhere 
[9,10]. 
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Hormonal Response to Supplementation 
The results of the ANCOVA revealed no effect of basal serum hormone 
concentrations on the hormonal response to AND-HB. Therefore, actual, rather than 
adjusted means from the ANCOVAs are presented throughout the text. 
Serum total testosterone concentrations were not different between age or treatment 
groups at baseline, nor were they altered by supplementation (Figure 1). 
Basal serum free testosterone concentrations were significantly related to age 
(1^=0.23), and were lower in the 50 year olds than the 30 year olds (Figure 2; P<0.05). For 
all ages combined, ingestion of AND-HB resulted in a mean increase (P<0.05) of 37% in 
serum free testosterone concentrations during weeks 1-4. There was no relationship between 
the change in serum free testosterone concentrations and age (^=0.08). 
Basal serum androstenedione concentrations were higher in the 30 year olds (P < 
0.05) than in the 40 or 50 year olds (Figure 3). For all ages combined ingestion of AND-HB 
resulted in a 174% increase (P < 0.05) in serum androstenedione concentrations during weeks 
1-4. The increase in serum androstenedione concentrations was not related to age (r2= 
0.029). 
Basal serum DHT concentrations were higher in the 30 year olds than in the 40 or 50 
year olds (P<0.05; Figure 4). For all ages combined, ingestion of AND-HB resulted in a 
57% increase (P < 0.05) in serum DHT concentrations during week 1-4. The increase in 
serum DHT concentration was not related to age (r^=0.033). 
Basal serum estradiol concentrations were not different between age or treatment 
groups (Figure 5). For all ages combined, ingestion of AND-HB resulted in an 86% increase 
(P < 0.05) in serum estradiol concentrations during weeks 1-4. There was no relationship 
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between the mean increase in serum estradiol concentrations and age (rW.029) or body 
mass index (1^=0.024). 
Age did not influence the changes in the testosterone to estradiol ratio. The ratio of 
total testosterone to estradiol for all ages combined decreased (P<0.05) during weeks 1-4 in 
AND-HB (109 ± 10 vs. 65 ± 5) and remained stable in PL (106 ± 9 vs. 113 ± 9). Similarly, 
for all ages combined, the ratio of free testosterone (pmol I"') to estradiol (pmoM1) decreased 
(P<0.05) during weeks 1-4 in AND-HB (0.37 ± 0.04 vs. 0.28 ± 0.02) and did not change in 
PL (0.37 ± 0.03 vs. 0.39 ± 0.03). 
Serum PSA concentrations were not affected by age or supplementation (Figure 6). 
The mean serum PSA concentrations throughout the 4 weeks of supplementation for all 
treatment groups combined were 2.1 ng ml"', 2.6 ng ml"' and 2.5 ng ml"' for the 30,40, and 
50 year olds, respectively. 
Serum Lipid Response 
For all ages combined, ingestion of AND-HB resulted in an 11% decrease (P < 0.05) 
in serum HDL-C concentration during weeks 1-4 (Table 2). The decrease in serum HDL-C 
concentrations was independent of age (r2=0.00l) but was positively related to pre-
supplementation HDL-C concentrations (r2=0.284). Serum low-density lipoprotein 
cholesterol (LDL-C) and total cholesterol (Total-C) concentrations were not altered by age or 
treatment. 
Blood Chemistry Response 
Serum concentrations of gamma-glutamyltransferase, aspartate aminotransferase, and 
alanine aminotransferase remained unchanged throughout the 4-week supplementation period 
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and were not affected by age. There was also no age or supplement related change in serum 
concentrations of protein, albumin, or globulin (data not shown). 
Dietary Analysis 
There were no age or treatment differences in dietary macronutrient intake (Table 3). 
There were also no age or treatment differences in saturated fat, monounsaturated fat, 
polyunsaturated fat, or cholesterol intake (Table 4). 
Discussion 
The current results demonstrate that chronic ingestion of 100 mg androstenediol taken 
t.i.d. does not increase serum total testosterone concentrations measured -8-10 h after intake. 
In addition, the use of herbal aromatase and 5a-reductase inhibitors does not prevent 
conversion of the ingested androstenediol to estradiol and DHT. However, unlike previous 
observations with chronic 100 mg b.i.d. androstenediol ingestion [4], chronic AND-HB 
ingestion elevates serum free testosterone concentrations. 
The ingestion of weak androgens, such as androstenedione and androstenediol, is 
claimed by nutritional supplement marketers to increase serum testosterone concentrations. 
Although comparing results across studies and subject populations should be done with 
caution, serum total testosterone concentrations are unchanged within a few hours of 
ingesting 100-200 mg androstenedione [3,11,12,13] or 8-12 h after ingesting 100-300 mg [4, 
9,11,12,13] androstenedione. The addition of herbal extracts does not change the 
testosterone response to androstenedione ingestion within 6 h of intake [11,12]. In vitro, 
androstenediol is converted to testosterone ~3 times more readily than androstenedione [2], 
suggesting that androstenediol ingestion would more effectively increase serum testosterone 
concentrations than androstenedione. In spite of the greater in vitro conversion of 
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androstenediol to testosterone, serum testosterone concentrations are not changed with 90 
min of 200 mg androstenediol intake [3] or at 12 h after 100 mg [4]. The current results 
indicate that the ingestion of herbal extracts does not change the serum total testosterone 
response to androstenediol. 
Although oral intake of 200 mg androstenediol does not increase serum total 
testosterone concentrations acutely [3], and intake of 100 mg androstenediol does not 
increase serum testosterone after ~8 h (present study), we have recently observed that 
sublingual intake of 20 mg androstenediol causes an acute -15% increase in serum total 
testosterone concentrations lasting for at least 3 hours [14]. It therefore appears that while 
androstenediol can be converted to testosterone, the processes of digestion and hepatic 
catabolism destroy much of the ingested androstenediol. 
Serum free testosterone concentrations are unchanged after ingestion of a single dose 
of 200 mg androstenediol [3] or chronic ingestion of 100 mg b.i.d. [4]. The increase in 
serum free testosterone concentrations observed in the present study may be due to the higher 
daily dose of androstenediol administered. Since we have previously observed that herbal 
extracts do not alter the hormonal response to androstenedione ingestion [10,12], it is 
unlikely that the increased serum free testosterone concentrations resulted from the addition 
of saw palmetto, yLA, indole-3-carbinol, chrysin, and Tribulus terrestris. 
Increased serum free testosterone in conjunction with unchanged total testosterone, 
protein, and albumin concentrations suggests that androstenediol ingestion may exert an 
affect on sex hormone binding globulin (SHBG). Since SHBG binds more favorably to DHT 
than testosterone [15], it is possible that androstenediol ingestion causes a shift in the binding 
of SHBG from testosterone to DHT resulting in increased serum free testosterone 
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concentrations. It is also possible that, similar to androstenedione ingestion [13], 
androstenediol ingestion results in reduced serum SHBG concentrations. Since we were 
unable to measure SHBG in the current study, the effect of androstenediol ingestion on 
SHBG remains unknown. 
The tracer analog method for measuring free testosterone has been criticized based on 
findings of a positive relationship between SHBG and measured free testosterone 
concentrations, and the suggestion that this method detects a constant fraction of the total 
testosterone concentrations, rather than the testosterone that is free from binding proteins 
[16]. The increased serum free testosterone concentrations with no concomitant increase in 
total testosterone concentrations in the present study suggests that the tracer analog method 
does not measure a constant fraction of serum total testosterone. This finding supports the 
work of others [17,18] demonstrating that this method accurately measures free testosterone 
concentrations, and suggests that the observed increased serum free testosterone 
concentrations are not an artifact of the method of measurement. 
Marketing claims purport that androstenediol ingestion enhances the effects of 
resistance training. On the contrary, Breeder et al. [4] found that androstenediol ingestion 
does not increase serum free testosterone concentrations or enhance muscle mass or strength 
gains associated with resistance training in men. Previous observations indicate that larger 
(~5 fold) increases in serum testosterone concentrations increase muscle protein synthesis 
and the adaptations to resistance training [19,20,21 ]. Since we did not assess muscle mass or 
strength, the effects of the 37% increase in serum free testosterone concentrations on muscle 
mass remain unknown. 
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The action of 5a reductase converts androgens into DHT [22], which has been 
associated with benign prostate hypertrophy [23]. In spite of the inclusion of yLA and saw 
palmetto, which inhibit 5a reductase in vitro [5,6], AND-HB ingestion results in increased 
serum DHT concentrations. Since the serum DHT response to androstenediol intake has not 
been previously examined, it is difficult to determine whether the inclusion of yLA and saw 
palmetto in AND-HB altered the serum DHT response. However, the increases in serum 
DHT concentrations with AND-HB intake were similar in magnitude to our previous 
observations with androstenedione [9]. Therefore, it appears that yLA and saw palmetto do 
not effectively inhibit the conversion of exogenous androgens into DHT. 
Some marketers of nutritional supplements claim that androstenediol does not 
undergo aromatization. However, elevated serum estradiol concentrations in conjunction 
with androstenediol intake have been reported [4,14], suggesting that androstenediol may 
undergo aromatization. Furthermore, the elevations in serum estradiol after ingestion of 100 
mg androstenediol t.i.d. are very similar in magnitude to those found after ingestion of 100 
mg androstenedione t.i.d. ingestion in a similar population [9,10] suggesting that 
androstenediol is aromatized to the same extent as androstenedione. 
In vitro, chrysin inhibits aromatase activity [7]. In vivo, indole-3-carbinol inhibits 
aromatization and enhances estrogen clearance [8]. However, the inclusion of these herbal 
extracts in AND-HB did not prevent elevated serum estradiol concentrations. Since Broeder 
et al. [4], used 200 mg/day androstenediol and the present study used 300 mg/day, and the 
increase in serum estradiol was of a larger magnitude in the present study, indole-3-carbinol 
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and chrysin do not appear to be effective at inhibiting aromatization in the presence of 
exogenous androgens. 
Similar to our previous observations with androstenedione ingestion [9,10], short-
term androstenediol ingestion does not alter serum PSA concentrations. Although this 
indicates that short-term androstenediol ingestion does not increase the risk of prostate 
cancer, the development of prostate cancer occurs slowly and is not always detectable with 
measurements of serum PSA [24]. 
The ingestion of androstenediol is purported to enhance health and vitality. However, 
the health related consequences of long-term androstenediol ingestion have not been 
examined and the hormonal milieu associated with chronic androstenedione ingestion may 
increase the risk for disease. The testosterone/androstenedione ratio is lower in patients with 
pancreatic cancer [25]. In the present study, the testosterone/androstenedione ratio after 
AND-HB intake was one half of that found in patients with pancreatic cancer [25], 
suggesting that AND-HB intake may predispose users to pancreatic cancer. A 20% increase 
in serum estradiol concentrations has been observed in men with myocardial infarction [26], 
and increased serum estradiol in conjunction with increased serum DHT has been 
experimentally demonstrated to induce benign prostate hyperplasia [23]. Furthermore, since 
relatively small (i.e., 1 nmol/L) increases in serum androstenedione are associated with a 
significant increases in the risk for prostate cancer, the -12 nmol/L increase in serum 
androstenedione observed with AND-HB intake may be of clinical relevance. The reduced 
serum HDL-C concentrations associated with androstenediol ingestion are indicative of an 
-12% increase in the risk for heart disease [27]. Although none of these conditions were 
observed during the present study, and it is unlikely that these chronic diseases would be 
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detected during the course of 4 weeks, untoward health consequences with long-term 
androstenediol intake cannot be ruled out. 
Conclusion 
Chronic ingestion of 100 mg androstenediol t.i.d. produces modest increases in serum 
free testosterone, and more pronounced increases in serum estradiol, androstenedione, and 
DHT concentrations while reducing serum HDL-C concentrations in 30-58 year old men. 
The changes in the serum hormonal milieu were observed in spite of the inclusion of saw 
palmetto, yLA, indole-3-carbinol, chrysin, and Tribulus terrestris suggesting that, in the doses 
given, these herbal extracts do not prevent the aromatization or 5a reduction of ingested 
androstenediol. Although the health related effects of long-term androstenediol ingestion are 
unknown, the observed changes in the serum hormone profile suggest that caution is 
advisable in its use as a nutritional supplement. 
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Table and Figures 
Table 1. Anthropometric data 
30 year olds 40 year olds 50 year olds 
PL AND-HB PL AND-HB PL AND-HB 
(n=10) (n=10) (n=10) (n=10) (n=7) (n=8) 
Age (y) 34±1 34±1 44 ± 1 43± 1 53± 1 53±1 
Height (cm) 181±4 177±3 182±2 180±2 174±3 175±2 
Body Mass (kg) 96±6 85 ±5 101±10 93±3 87±7 93±7 
BMI (kg/m2) 29±2 27±2 30±2 29± 1 29±2 27±1 
Data are means ± SE. 
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Table 2. Serum cholesterol concentrations during four weeks of supplementation 
30's 40's 50's 
PL AND-HB PL AND-HB PL AND-HB 
Week (n=10) (n=10) (n=10) (n=10) (n=7) (n=8) 
HDL-C 0 0.95±0.06 1.09±0.08 0.98±0.11 1.09±0.06 1.23±0.13 1.09±0.08 
1 0.94±0.06 0.97±0.06* 0.99±0.10 0.96±0.07* 1.21 ±0.13 1.00±0.09* 
2 0.90±0.06 0.94±0.07* 0.99±0.09 0.89±0.05* 1.22±0.13 0.93±0.08* 
3 0.93±0.07 0.96±0.05* 1.00±0.09 0.92±0.04* 1.27±0.13 0.97±0.09* 
4 0.96±0.07 0.95±0.06* O.99±O.lO 0.93±0.05* 1.21±0.13 0.95±0.11* 
LDL-C 0 3.0±0.2 3.0±0.3 3.1±0.3 3.0±0.2 3.3±0.3 3.1 ±0.2 
1 2.8±0.3 3.1 ±0.2 3.4±0.3 2.9±0.1 3.4±0.4 2.9±0.I 
2 3.0±0.2 3.1 ±0.2 3.5±0.5 3.0±0.2 3.5 ±0.3 2.9±0.1 
3 2.7±0.3 3.2±0.3 3.4±0.4 2.9±0.2 3.7±0.3 2.9±0.2 
4 2.8±0.2 2.9±0.3 3.1 ±0.3 3.0±0.2 3.6±0.2 2.9±0.2 
Total-C 0 4.3±0.5 4.7±0.4 4.9±0.4 4.8±0.2 5.4±0.3 4.68±0.3 
1 4.6±0.23 5.0±0.3 5.2±0.4 4.6±0.1 5.5±0.4 4.6±0.6 
2 4.7±0.3 4.9±0.3 5.2±0.5 4.7±0.2 5.5±0.4 4.6±0.5 
3 4.4±0.3 4.9±0.3 5.0±0.4 4.5 ±0.2 5.7±0.4 4.5±0.6 
4 4.5 ±0.3 4.8±0.3 4.9±0.4 4.7±0.2 5.5±0.2 4.6±0.6 
Data are means ± SE. Units are mmoL/L. * Significantly different from week 0 for AND-HB 
(Treatment-by-Week effect, P < 0.05) 
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Table 3. Dietary macronutrient intake during four weeks of supplementation 
Week 
30's 
PL AND-HB 
(n=10) (n=10) 
40's 
PL AND-HB 
(n=I0) (n=10) 
50's 
PL AND-HB 
(n=7) (n=8) 
KJ 103 0 10.0±0.7 9.7±0.9 9.6±0.8 7.8±1.1 8.5 ±1.3 9.5±0.5 
1 9.9± 1.0 10.1 ±0.7 10.0±1.2 9.3 ±0.7 8.7±1.2 10.8±0.5 
2 10.7±0.8 9.5±0.8 I0.8±l.l 9.7±0.6 8.8±0.8 9.7±1.2 
3 9.9±0.8 9.7±0.6 
4 9.8±0.7 11.1±0.9 
8.8±1.1 9.9±0.8 8.6±0.7 9.1 ±0.9 
9.8±0.9 9.2±0.7 7.1 ±1.0 9.7±1.0 
CHO (g) 0 331 ±29 346±30 330±29 287±25 286±71 323±30 
1 339±42 344±36 
2 366±34 346±34 
3 346±21 364±36 
4 340±26 383±42 
338±47 330±31 296 ±42 349±34 
322±34 318 ±31 298 ±46 314±43 
290±43 323 ±35 288±37 336±54 
348±40 301 ±34 217±17 333±47 
Fat (g) 0 78±8 58±11 
1 77 ±10 68±6 
83± 10 61 ±9 
70±12 57±7 
76±12 71 ±8 
68±10 
72±10 
93 ±16 
62 ±6 
68± 10 
71 ±6 
64 ±8 
70±5 
73 ±9 
67 ±5 
51 ±9 
58± 12 
59±5 
60±6 
56± 12 
67±6 
88±4 
76± 12 
56±9 
72±10 
Data are means ± SE. 
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Table 4. Dietary fat and cholesterol intake during four weeks of supplementation 
30's 
PL AND-HB 
Week (n=10) (n=10) 
40's 
PL AND-HB 
(n=10) (n=10) 
50's 
PL AND-HB 
(n=7) (n=8) 
Sat (g) 0 25.9±3.5 21.7±5.0 20.8±3.9 24.5 ±2.6 15.3±3.5 22.1±3.0 
1 24.1 ±2.8 24.6±3.4 24.0±3.6 20.1 ±2.4 I6.9±2.4 26.8±2.6 
2 27.9±3.5 21.5±4.6 29.7±6.3 23.2±3.1 20.2±3.0 21.8±3.1 
3 23.2±4.1 20.8±2.7 20.0±2.5 22.7±2.5 18.9±2.2 18.3±3.6 
4 26.1 ±4.9 23.3±3.7 I9.0±2.2 23.8±1.9 18.6±4.6 23.1 ±3.4 
Mon (g) 0 23.4±2.8 18.0±3.4 17.9±2.0 21.8±1.9 17.8±4.4 19.5±2.6 
1 23.5±5.0 24.8±2.4 24.8±3.6 19.4 ±2.7 19.7±6.0 32.2±2.5 
2 26.2±4.9 18.6±2.7 33.1 ±6.4 23.2±2.5 18.4±2.0 23.8±3.8 
3 20.7±3.9 17.7±2.7 18.5±3.1 24.2 ±4.2 17.8±2.6 2I.0±3.8 
4 20.8±3.1 26.1 ±3.4 22.7±3.0 20.5±2.5 16.5±4.7 18.1±3.0 
Chi (mg) 0 311 ±60 246±48 264±43 330±52 247±48 259±75 
1 245 ±52 273±54 193 ±34 248 ±45 155±32 366±70 
2 265±59 184±30 327±82 275±45 251±64 271±51 
3 185 ±38 133±25 366± 165 332±76 228±41 260±63 
4 204±38 290±57 200±26 337±68 158±39 289 ±84 
Data are means ± SE. Sat = saturated fat, Mon = monounsaturated fat, Chi = cholesterol 
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Abstract 
The effectiveness of orally ingested androstenediol in raising serum testosterone 
concentrations may be limited due to hepatic breakdown of the ingested androgens. Since 
androstenediol administered sublingually with cyclodextrin bypasses first pass hepatic 
catabolism, we evaluated the acute hormonal response to sublingual cyclodextrin 
androstenediol supplement in young men. Eight males experienced in strength training (22.9 
± 1.2 y) consumed either 20 mg androstenediol in a sublingual cyclodextrin tablet (SL-
DIOL) or placebo (PL) separated by at least one week in a randomized, double blind cross 
over manner. Blood samples were collected before supplementation and at 30-min intervals 
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for 3 h following supplementation. Serum hormone concentrations did not change in PL. 
Serum androstenedione concentrations were increased (P<0.05) above baseline (11.2 ±1.1 
nmol-L"') in SL-DIOL from 60-180 min after intake, and reached a peak concentration of 
25.2 ± 2.9 nmol-L"1 at 120 min. Serum free testosterone concentrations were increased from 
86.2 ± 9.1 pmol-L"1 in SL-DIOL from 30 to 180 min, and reached a peak concentration of 
175.4 ± 12.2 pmol-L"1 at 60 min. Serum total testosterone concentrations increased above 
basal (25.6 ± 2.3 nmol-L"') from 30-180 min in SL-DIOL, and reached a peak concentration 
of 47.9 + 2.9 nmol-L"1 at 60 min. Serum estradiol concentrations were elevated (P<0.05) 
above baseline (0.08 ± 0.01 nmol-L"') from 30-180 min in SL-DIOL and reached 0.14 ± 0.02 
nmol-L"' at 180 min. These data indicate that sublingual cyclodextrin androstenediol intake 
increases serum androstenedione, free testosterone, total testosterone, and estradiol 
concentrations. 
Introduction 
The intake of weak androgens is advertised to increase serum testosterone 
concentrations. However, increasing serum testosterone concentrations through the ingestion 
of weak androgens appears to be limited by hepatic catabolism of the ingested androgen. 
While ~3% of serum androstenedione and -15% of androstenediol can be converted to 
testosterone (5), as much as -89% of orally administered androstenedione may be 
catabolized into glucuronides before it can enter the extrasplanchnic circulation, and -98% of 
testosterone formed from orally infused androstenedione undergoes hepatic extraction (15). 
Consistent with these findings, oral intake of 100-200 mg androstenedione (6,8,11,17,19,25) 
or androstenediol (6,11) do not change serum testosterone concentrations in men. Therefore, 
a mode of androgen delivery that bypasses first pass hepatic catabolism may enhance the 
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conversion of a precursor steroid into testosterone and increase serum testosterone 
concentrations in men. 
Androstenediol can be reversibly converted to testosterone, androstenedione, and 
dehydroepiandrosterone (DHEA) (5,16). In addition to androgenic interconversion, the 
aromatization of these androgens produces the majority of serum estrogens in men (4,21). 
The effect of androstenediol supplementation on serum estrogens in young men has not been 
previously explored. 
A cyclodextrin compound is a cyclic oligosaccharide formed from the enzymatic 
degradation of starch, which forms an inclusion complex with steroid hormones facilitating 
the passage of the steroid across the oral mucosa while the ingested cyclodextrin undergoes 
digestion (10,28). The sublingual delivery of a hydroxypropyl-P-cyclodextrin compound 
containing small doses of testosterone produces ~5 fold increases in serum testosterone 
concentrations in men (24,26,28). Since the hormonal responses to sublingual cyclodextrin 
androstenediol have not been previously examined, the purpose of this investigation was to 
evaluate the acute serum hormonal response to sublingual cyclodextrin androstenediol in 
young men. 
Methods 
Approach to the Problem 
Although changes in serum hormones in men are observed within 2 hours after 
ingesting a weak androgen, the lack of meaningful increases in serum testosterone 
concentrations suggests a large hepatic catabolism of the weak androgens. Since sublingual 
delivery avoids first pass clearance and cyclodextrins facilitate diffusion of an androgen 
across the oral mucosa, the presence or lack of effectiveness of sublingual cyclodextrin 
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androstenediol in increasing serum testosterone as well as other hormones should be evident 
within 3 hours of intake. 
Subjects 
Eight males experienced in strength training (22.9 ± 1.2 y; 180.6 ± 2.0 cm; 83.0 ± 2.0 
kg; 12.7 ± 1.7% body fat) volunteered to participate in this study. Subjects completed a 
written medical history to eliminate persons with a known chronic disease, abuse of alcohol, 
or illicit drugs. Subjects also completed a questionnaire regarding exercise history and use of 
nutritional supplements. Prior to participation in this project, approved by the Iowa State 
University human subjects review board, all subjects signed an informed consent. 
Blood Sample Collections 
Following an overnight fast, subjects reported to the laboratory between 5:30 and 
7:00 a.m. After insertion of a flexible catheter into an antecubital vein, blood samples were 
collected without stasis from sitting subjects 20 min before supplementation, immediately 
prior to supplementation, and at 30-min intervals for 3 h after supplement administration. 
Blood samples were allowed to clot in an ice bath until centrifugation and serum separation. 
Dietary Control 
Subjects were instructed to eat their normal diet and record dietary intake and 
exercise for three days prior to the initial trial and repeat the same diet and exercise protocol 
for the subsequent trial. Dietary records were analyzed using commercial software 
(Nutritionist 4, N-Squared computing, San Bruno, CA). 
Supplementation 
Subjects were administered either placebo (rice flour; PL) or sublingual 
hydroxypropyl-p-cyclodextrin androstenediol (SL-DIOL) in a randomly assigned, double 
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blind, cross over manner separated by a period of at least 7 days. Supplements were 
administered as an unmarked white capsule that was swallowed (PL) or an unmarked white 
tablet that was placed under the tongue and allowed to completely dissolve (SL-DIOL). 
Subjects and research assistants were informed that the purpose of the study was to evaluate 
the effectiveness of either an ingested or sublingual supplement. The SL-DIOL (Cyclo-Diol, 
Kaizen™ Inc, Los Angeles, CA) was analyzed for hormone content using HPLC (Integrated 
Bio-molecule Inc., Tucson, AZ) and each tablet contained 21.4 mg androstenediol, 3.7 mg 
androstenedione, and no other steroid hormones. 
Body Composition 
Hydrostatic weight was determined using a computer interfaced load cell. After 
estimation of residual volume from the measurement of maximal voluntary lung capacity 
(13) using a computerized spirometer (PC Flow+ for Windows, Spirometries Medical 
Equipment Co., Grey, ME) percent body fat was calculated using the Siri equation (27). 
Hormonal Analysis 
Serum concentrations of total and free testosterone, androstenedione, and estradiol 
were measured in duplicate via commercial tracer analog radioimmunoassay (RIA; Coat-A-
Count, Diagnostic Products Corp, Los Angeles, CA). When the serum hormone 
concentrations exceeded the highest calibrator value provided with the RIA kit, the sample 
was reanalyzed according to the manufacturers instructions by diluting the sample with 
reagent containing no hormone. The accuracy of the RIA kits was verified by analyzing 
samples of known hormone concentrations. The intra assay coefficients of variation for total 
testosterone, free testosterone, androstenedione, and estradiol were 5.9%, 5.8%, 5.2% and 
6.1%, respectively. No data on the cross reactivity of androstenediol with the other steroid 
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hormone assays are available. According to the manufacturer of the RIA kits, cross 
reactivity is less than 0.5%, except for a 1.49% cross reactivity of the androstenedione assay 
for testosterone. 
Calculations and Statistics 
Data were analyzed using commercial software (SPSS Inc, Chicago IL). Statistical 
analyses were performed using a 2 factor (supplement by time) repeated measures analysis of 
variance (ANOVA). Specific mean differences were analyzed with a student Newman-Keuls 
post hoc test. Data are presented throughout the text as means ± SE. Percent changes in 
hormones were calculated as the mean increase above baseline during the 3 h after 
supplement intake. Area under the curve (AUC) was calculated using the trapezoidal model. 
Peak hormone concentrations were defined as the numerically highest concentrations reached 
for each subject during the time course of the study. 
Results 
Subjects 
All subjects were students at Iowa State University and reported participation in a full 
body resistance-training program for 6.0 ± 1.1 years. Subjects participated in resistance 
training 3.6 ± 0.5 days per week for 1.6 ± 0.2 h per exercise session. Five subjects reported 
regular participation in aerobic exercise 3.0 ± 0.5 days per weeks for 20 ± 3.2 min per 
session. Although no subjects reported participation in competitive weight lifting or 
bodybuilding, one subject was a collegiate track athlete. None of the subjects reported any 
current or previous use of anabolic steroids, only 2 subjects reported previous use of 
nutritional supplements (creatine n=2, "weight gain powder" n=l) and no subject consumed 
any supplements during the 9 months prior to study. 
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Supplementation. Dissolution of SL-DIOL required 12.4 ± 1.4 min after the tablet was 
placed sublingually. 
Dietary Intake 
Subjects reported a mean daily energy intake of 8,770 ± 904 Kj-d"' for three d prior to 
the initial trial, and repeated the same diet for the subsequent trial. Daily dietary intake was 
161 ± 60 g-d"' (26 ± 6%) protein, 268 ± 49 g-d"1 (46 ± 6%) carbohydrate, and 68 ± 9 g-d"' (37 
± 3%) fat. 
Hormonal Response 
Serum hormone concentrations did not change in PL. Serum androstenedione 
concentrations were increased from 60 - 180 min in SL-DIOL (Figure 1; P<0.05) while peak 
concentrations of 24.3 ± 1.5 nmol-L"1 were observed 150 min after administration. The AUG 
for serum androstenedione concentrations was higher (P<0.05) in SL-DIOL (1,604.9 ± 136.3 
nmol/Lmin) compared with PL (96.0 ± 50.0 nmol/Lmin). 
SL-DIOL increased serum free testosterone concentrations (Figure 2; P<0.05) from 30 - 180 
min after administration while peak concentrations (175.4 ± 2.2 pmol-L"1) were observed 60 
min after supplementation. The AUG for serum free testosterone concentrations was higher 
(P<0.05) in SL-DIOL (11,137 ± 1,573 pmol/L-min) compared with PL (750 ±218 
pmol/L-min). Serum free testosterone concentrations increased in all subjects in response to 
SL-DIOL. 
SL-DIOL intake increased serum total testosterone concentrations (P<0.05; Figure 3) 
above basal (25.6 ± 2.3 nmol-L"') from 30-180 min and peak serum total testosterone 
concentrations were observed at 60 min (47.9 ± 2.9 nmol-L"'). The AUG for total 
testosterone was higher (P<0.05) in SL-DIOL (2,673 ± 577 nmol/Lmin) compared with PL 
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(204 ± 108 nmol/L min). Serum total testosterone concentrations were elevated in all 
subjects after SL-DIOL intake. The calculated effect size for the comparison of basal total 
testosterone concentrations to those observed at 60 min was large (0.89), emphasizing the 
effect of SL-DIOL intake on serum total testosterone concentrations. 
Serum estradiol concentrations were increased above basal (0.08 ± 0.01 nmol-L"1) 30 
- 180 min after administration in SL-DIOL (P<0.05; Figure 4) and reached 0.14 ± 0.02 
nmol-L"1 180 min after SL-DIOL administration. The AUC for serum estradiol 
concentrations was greater (P<0.05) for SL-DIOL (5.26 ± 0.86 nmol/L-min) compared with 
PL (1.12 ± 0.44 nmol/Lmin). 
Discussion 
The main finding of this study is that -20 mg cyclodextrin androstenediol taken 
sublingually increases serum testosterone and estradiol concentrations in healthy young men. 
Since a single 200 mg dose of androstenediol taken orally does not change serum free or total 
testosterone concentrations in young men (11), the current findings suggest that sublingual 
cyclodextrin is superior to oral ingestion for the delivery of androstenediol to the peripheral 
tissues and subsequent conversion to testosterone. 
SL-DIOL contained both androstenediol (21.4 mg/tablet) and androstenedione (3.7 
mg/tablet). Since both androstenedione and androstenediol can be converted to testosterone 
(5,14,16) it is possible that the increases in serum testosterone were at least partially due to 
the conversion of androstenedione, and not androstenediol, to testosterone. However, serum 
testosterone concentrations were elevated at 30 min after intake, while serum 
androstenedione concentrations were not elevated until 60 min after intake. Furthermore, we 
have observed that increases in the serum androstenedione concentration of a magnitude 
130 
greater than that observed in the present study do not increase serum testosterone 
concentrations (8,17). Therefore, the increased testosterone concentrations are likely due 
solely to the androstenediol contained in SL-DIOL. 
Sublingual cyclodextrin testosterone intake results in peak serum testosterone 
concentrations 20-30 min after intake (26,28), while SL-DIOL results in peak serum 
testosterone concentrations ~ 60 min after intake. In hypogonadal men, 2.5-10 mg 
cyclodextrin testosterone administered sublingually causes serum testosterone concentrations 
to reach supranormal levels (-35-85 nmol-L"1) within 60-90 min. Serum testosterone 
concentrations in these men return rapidly to values below the normal range within 3 h, and 
return to baseline concentrations by 6 h with a half-time of < 2 h (24,26,28), suggesting that 
effective therapy with sublingual cyclodextrin testosterone would require administration 
every 2 h (28). Since serum testosterone concentrations after SL-DIOL intake remained -
40% above baseline at 180 min it is unknown how long serum testosterone concentrations 
remain elevated after cyclodextrin androstenediol intake in eugonadal men. However, 
allowing for the 30-40 min delay in the testosterone response following SL-DIOL, the 
change in serum testosterone concentrations is similar to the pattern exhibited after 
sublingual cyclodextrin testosterone intake (24,26,28). Therefore, it is likely that sustained 
increases in serum testosterone with sublingual cyclodextrin androstenediol would also 
require frequent dosing. 
Androstenediol intake is advertised to enhance muscle mass and strength gains during 
resistance training. However, chronic ingestion of androstenediol does not enhance the 
adaptations to resistance training in men (6). In contrast to oral androstenediol ingestion 
(6,11), SL-DIOL increased serum testosterone concentrations. It is currently unknown if a 
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transient increase in serum testosterone of the magnitude elicited by SL-DIOL intake alters 
muscle mass or strength. 
The tracer analog method for measuring free testosterone has been criticized recently 
based on findings of a positive relationship between SHBG and measured free testosterone 
concentrations (30). In addition it has been stated that this method detects a constant fraction 
of the total testosterone concentrations, rather than the testosterone that is free from binding 
proteins (30). However, others have concluded that the tracer analog method accurately 
measures free testosterone concentrations (18,23). The finding that both free and total 
testosterone concentrations are significantly increased after SL-DIOL intake suggests that 
androstenediol taken sublingually is converted to testosterone. 
As previously observed with sublingual cyclodextrin testosterone intake (26,28), 
sublingual cyclodextrin androstenediol increases serum estradiol concentrations, suggesting 
that a significant portion of the increased serum testosterone and/or exogenous androgen 
underwent aromatization (20). Oral ingestion of androstenedione or androstenediol increases 
serum estrogens but not serum testosterone concentrations (6,7,8,17,19,25) indicating 
aromatization of the weak androgen. In the present study it was not possible to determine 
whether the elevated serum estradiol concentrations result from the exogenous 
androstenediol, or from the serum testosterone formed from the androstenediol, or both. 
Based upon the findings with ingested androstenedione (6,7,8,17,19,25), and sublingual 
cyclodextrin testosterone (26,28), the increased serum estradiol concentrations associated 
with SL-DIOL are likely to remain elevated for a longer period of time than will testosterone. 
Furthermore, we have recently observed that the increases in serum estrogens with chronic 
androstenediol intake are larger than the increases in serum testosterone (unpublished 
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observations). These findings may be clinically significant, since elevated estradiol 
concentrations are associated with benign prostate hypertrophy (15) and gynecomastia (4). 
In contrast to the high individual variability in the hormonal response to 
androstenedione ingestion (19), all of the subjects exhibited similar increases in serum 
testosterone, androstenedione, and estradiol concentrations in response to SL-DIOL intake. 
Salehian et al. (26) observed that the hormonal response to sublingual cyclodextrin 
testosterone was not different between the first dose and subsequent doses during a 60 d 
treatment regimen, indicating that there is no change in the absorption of a sublingually 
administered androgen with prolonged use. In contrast, there is a reduction in the hormonal 
response to prolonged ingestion of androstenedione (6,8,17) and DHEA (9,22) suggesting 
either reduced entry into or enhanced clearance of the androgen from the circulation, or an 
alteration in the enzymatic transformation of weak androgens into other hormones in 
response to prolonged intake. Thus, although it appears that a single dose of SL-DIOL 
produces a uniform hormonal response in young strength trained men; the hormonal response 
to prolonged use of SL-DIOL is unknown. 
Chronic oral intake of androstenediol lowers serum high-density lipoprotein 
cholesterol concentrations (6, unpublished observations). Chronic androstenediol intake also 
elevates serum dihydrotestosterone concentrations (unpublished observations), which 
combined with elevated estradiol concentrations may also contribute to benign prostate 
hypertrophy (29). Increased serum concentrations of androstenedione have been associated 
with pancreatic cancer in men (12). The effects of a transient increase in serum testosterone 
concentrations have not been evaluated. While low endogenous testosterone concentrations 
may be related to diabetes and hypertension (2,3), increased serum testosterone 
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concentrations may cause a deterioration of the blood lipid profile (1). These findings raise 
the possibility that more long-term use of sublingual androstenediol may pose significant 
health risks. 
In conclusion, the use of a sublingual cyclodextrin androstenediol nutritional 
supplement causes rapid, and transient increases in serum testosterone concentrations. 
Sublingual cyclodextrin androstenediol also causes increases in serum estradiol and 
androstenedione concentrations. The effects of the altered hormonal milieu observed after 
sublingual cyclodextrin androstenediol intake on health or the adaptations to resistance 
training are not known. 
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Figure 1. 
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Serum androstenedione concentrations after administration of placebo or 
sublingual cyclodextrin androstenediol (SL-DIOL). 
* different from 0 and -20 min (P < 0.05) 
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Serum free testosterone concentrations after administration of placebo or 
sublingual cyclodextrin androstenediol (SL-DIOL). 
* different from 0 and -20 min (P < 0.05) 
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Figure 3. Serum total testosterone concentrations after administration of placebo or 
sublingual cyclodextrin androstenediol (SL-DIOL). 
* different from 0 and -20 min (P < 0.05) 
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CHAPTER 7. CONCLUSIONS 
The current findings indicate that there is an age difference in the serum testosterone 
response to testosterone precursor intake. In young men (23 y), ingesting 100 mg 
androstenedione t.i.d. does not alter serum testosterone concentrations, while in 30-60 year 
old men the same dosage of testosterone precursor causes an -40% chronic increase in serum 
free testosterone. Since these older men had lower free and total testosterone concentrations 
than the previously investigated young men, it would appear that basal endogenous 
testosterone concentrations do alter the testosterone response to testosterone precursor intake. 
However, the physiologic significance of this moderate increase in free testosterone is 
unknown. 
The findings of this project also demonstrate that there is no difference in the 
hormonal response to androstenedione, androstenedione plus DHEA, or androstenediol 
intake. Taking these data along with previous results, indicate that in normal 20-60 year old 
men, DHEA intake does not enhance serum testosterone or alter serum estrogen 
concentrations. In contrast to advertised claims, orally ingested androstenediol does not 
increase serum testosterone concentrations more effectively than androstenedione. 
The current project also demonstrates that ingesting androstenedione or 
androstenediol increases serum estrogen and DHT concentrations. The increase in serum 
estradiol and DHT concentrations (-85 and 70%, respectively) associated with testosterone 
precursor intake in the present studies are close to the level used to experimentally induce 
BPH in dogs over a course of 9 weeks (-108 and 105%, for estradiol and DHT respectively), 
suggesting that prolonged use of testosterone precursors may cause untoward health 
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consequences. The serum testosterone, estradiol, and DHT response to androstenedione or 
androstenediol intake is not altered by the addition of saw palmetto, yLA, chrysin, I3C, or 
TT. These findings are in agreement with previous findings in young men. 
Finally, the current data indicate that sublingual administration of smaller doses of 
androstenediol and androstenedione effectively bypasses digestive and hepatic catabolism, 
delivering the testosterone precursor to peripheral tissue where it can be converted into 
testosterone. This mode of delivery would appear to have more promise for testosterone 
enhancement than does an ingested product. 
Future Directions 
Although the current project answers some questions regarding the age related 
response to testosterone precursor intake, there are a great many questions that still need to 
be addressed. Future research in this area should evaluate the effects of higher doses of 
testosterone precursor intake since it is widely believed that athletes are taking much greater 
doses than have been currently studied. Therefore, future investigations should examine both 
the acute and long-term hormonal and physiologic responses to ingesting large doses (> 300 
mg/day) of testosterone precursors. 
It was observed that testosterone precursor intake causes changes in the hormonal and 
cholesterol milieu that may impair health. However, the long-term consequences of these 
changes are unknown. It is also unknown if these changes are reversed after cessation of 
testosterone precursor intake. Therefore, a fertile area for future research is in the area of the 
health consequences of long-term testosterone precursor intake. 
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Finally, since sublingual administration of 20 mg androstenediol acutely increases 
serum testosterone concentrations, it would be of interest to evaluate the time course for 
these changes, and the effects of long-term use of sublingual testosterone precursor. 
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